PDHK1
Normalized values from positional scanning peptide array
TYR version of PSPA with Y as phospho-acceptor
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| O00141 | S422 | GPS6 | SGK1 SGK | PDsVLVTAsVKEAAEAFLGFsYAPPTDSFL___________ |
| O00141 | T256 | GPS6 | SGK1 SGK | IVLTDFGLCKENIEHNsTtstFCGtPEyLAPEVLHKQPYDR |
| O15530 | S241 | GPS6 | PDPK1 PDK1 | ITDFGTAKVLSPESKQARANsFVGtAQYVSPELLTEKSACK |
| O15530 | S25 | GPS6 | PDPK1 PDK1 | TSQLyDAVPIQSSVVLCSCPsPSMVRTQtESstPPGIPGGS |
| O15530 | S393 | GPS6 | PDPK1 PDK1 | yGNyDNLLSQFGCMQVSSSSssHsLsASDTGLPQRSGsNIE |
| O15530 | S396 | GPS6 | PDPK1 PDK1 | yDNLLSQFGCMQVSSSSssHsLsASDTGLPQRSGsNIEQYI |
| O15530 | S410 | GPS6 | PDPK1 PDK1 | SSSssHsLsASDTGLPQRSGsNIEQYIHDLDSNSFELDLQF |
| O15530 | T513 | GPS6 | PDPK1 PDK1 | VLKGEIPWSQELRPEAKNFKtFFVHTPNRTYYLMDPSGNAH |
| O43707 | Y878 | Sugiyama | ACTN4 | DKNFITAEELRRELPPDQAEyCIARMAPyQGPDAVPGALDy |
| O60361 | Y136 | Sugiyama | NME2P1 | SLRFKPEELVDYKSCAHDWVyE___________________ |
| O60664 | Y95 | Sugiyama | PLIN3 M6PRBP1 TIP47 | VsGAQPILSKLEPQIAsAsEyAHRGLDKLEENLPILQQPTE |
| P04075 | S336 | Sugiyama | ALDOA ALDA | GKKENLKAAQEEYVKRALANsLACQGKytPsGQAGAAAsEs |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04075 | S46 | Sugiyama | ALDOA ALDA | PGKGILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtA |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P05106 | T777 | GPS6 | ITGB3 GP3A | EEERARAKWDtANNPLyKEAtstFtNItyRGt_________ |
| P05106 | T779 | GPS6|iPTMNet | ITGB3 GP3A | ERARAKWDtANNPLyKEAtstFtNItyRGt___________ |
| P07437 | Y50 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | IDPTGtyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEP |
| P07900 | S63 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | IFLRELIsNssDALDKIRyEsLtDPsKLDsGKELHINLIPN |
| P08238 | S468 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | RRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKsIyyItG |
| P08238 | S470 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | RLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKsIyyItGEs |
| P08238 | S58 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | IFLRELIsNAsDALDKIRyEsLtDPsKLDsGKELKIDIIPN |
| P08559 | S232 | iPTMNet|PSP | PDHA1 PHE1A | ALWKLPCIFICENNRYGMGtsVERAAAsTDYYKRGDFIPGL |
| P08559 | S293 | GPS6|ELM|iPTMNet|PSP | PDHA1 PHE1A | CRSGKGPILMELQTYRyHGHsMsDPGVsyRtREEIQEVRsK |
| P08559 | S300 | GPS6|ELM|iPTMNet|PSP | PDHA1 PHE1A | ILMELQTYRyHGHsMsDPGVsyRtREEIQEVRsKsDPIMLL |
| P0DPH7 | S48 | Sugiyama | TUBA3C TUBA2 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| P11142 | S40 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P11142 | Y41 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P12814 | Y859 | Sugiyama | ACTN1 | DKNyITMDELRRELPPDQAEyCIARMAPYTGPDSVPGALDY |
| P13639 | S38 | Sugiyama | EEF2 EF2 | NIRNMsVIAHVDHGKStLtDsLVCKAGIIAsARAGEtRFtD |
| P13667 | S379 | Sugiyama | PDIA4 ERP70 ERP72 | QPEKFQSKYEPRSHMMDVQGstQDsAIKDFVLKyALPLVGH |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P15531 | S122 | Sugiyama | NME1 NDPKA NM23 | GtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELVDy |
| P17066 | S42 | Sugiyama | HSPA6 HSP70B' | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P17066 | Y43 | Sugiyama | HSPA6 HSP70B' | FQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAAL |
| P22392 | Y151 | Sugiyama | NME2 NM23B | SLWFKPEELVDyKSCAHDWVyE___________________ |
| P22626 | S212 | Sugiyama | HNRNPA2B1 HNRPA2B1 | EMQEVQssRsGRGGNFGFGDsRGGGGNFGPGPGsNFRGGsD |
| P23443 | S427 | GPS6 | RPS6KB1 STK14A | VFLGFtYVAPSVLESVKEKFsFEPKIRsPRRFIGsPRtPVs |
| P23443 | T252 | GPS6 | RPS6KB1 STK14A | VKLTDFGLCKEsIHDGTVtHtFCGTIEYMAPEILMRSGHNR |
| P23443 | T390 | iPTMNet | RPS6KB1 STK14A | KPLLQsEEDVsQFDSKFtRQtPVDsPDDstLsEsANQVFLG |
| P23443 | T412 | GPS6 | RPS6KB1 STK14A | VDsPDDstLsEsANQVFLGFtYVAPSVLESVKEKFsFEPKI |
| P26232 | T657 | Sugiyama | CTNNA2 CAPR | EDDsDFEQEDYDVRsRtsVQtEDDQLIAGQsARAIMAQLPQ |
| P28066 | Y8 | Sugiyama | PSMA5 | _____________MFLTRsEyDRGVNtFsPEGRLFQVEyAI |
| P29692 | S162 | Sugiyama | EEF1D EF1D | AKKPAtPAEDDEDDDIDLFGsDNEEEDKEAAQLREERLRQY |
| P29803 | S230 | PSP | PDHA2 PDHAL | ALWKLPCVFICENNLYGMGTsTERAAASPDYYKRGNFIPGL |
| P29803 | S291 | PSP | PDHA2 PDHAL | CRSGKGPILMELQTYRyHGHsMsDPGVsyRtREEIQEVRsK |
| P29803 | S298 | PSP | PDHA2 PDHAL | ILMELQTYRyHGHsMsDPGVsyRtREEIQEVRsKRDPIIIL |
| P31749 | S473 | GPS6 | AKT1 PKB RAC | DQDDSMECVDSERRPHFPQFsysAsGtA_____________ |
| P31749 | T308 | GPS6 | AKT1 PKB RAC | IKITDFGLCKEGIKDGAtMKtFCGtPEyLAPEVLEDNDyGR |
| P31751 | T309 | GPS6 | AKT2 | IKITDFGLCKEGISDGATMKtFCGtPEyLAPEVLEDNDyGR |
| P31943 | Y266 | Sugiyama | HNRNPH1 HNRPH HNRPH1 | yNGYNDGYGFGSDRFGRDLNyCFsGMsDHRyGDGGstFQst |
| P34931 | S42 | Sugiyama | HSPA1L | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P34931 | Y43 | Sugiyama | HSPA1L | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P35221 | T658 | Sugiyama | CTNNA1 | LDDsDFEtEDFDVRsRtsVQtEDDQLIAGQsARAIMAQLPQ |
| P36507 | S226 | GPS6 | MAP2K2 MEK2 MKK2 PRKMK2 | GEIKLCDFGVsGQLIDsMANsFVGtRSYMAPERLQGTHYSV |
| P48643 | S270 | Sugiyama | CCT5 CCTE KIAA0098 | ILTCPFEPPKPKTKHKLDVtsVEDyKALQKYEKEKFEEMIQ |
| P48741 | S42 | Sugiyama | HSPA7 HSP70B | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P48741 | Y43 | Sugiyama | HSPA7 HSP70B | FQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAAL |
| P54652 | S41 | Sugiyama | HSPA2 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P54652 | Y42 | Sugiyama | HSPA2 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P55060 | S342 | Sugiyama | CSE1L CAS XPO2 | ASVCERPHYKNLFEDQNtLtsICEKVIVPNMEFRAADEEAF |
| P55795 | Y266 | Sugiyama | HNRNPH2 FTP3 HNRPH2 | YGGYNDGYGFGSDRFGRDLNyCFsGMsDHRyGDGGssFQst |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P62258 | S148 | Sugiyama | YWHAE | YHRyLAEFAtGNDRKEAAENsLVAyKAAsDIAMtELPPTHP |
| P68363 | S48 | Sugiyama | TUBA1B | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q02156 | T566 | GPS6 | PRKCE PKCE | CKLADFGMCKEGILNGVTTTtFCGTPDyIAPEILQELEYGP |
| Q02750 | S222 | GPS6 | MAP2K1 MEK1 PRKMK1 | GEIKLCDFGVsGQLIDsMANsFVGtRSYMsPERLQGTHYSV |
| Q05513 | T410 | GPS6 | PRKCZ PKC2 | IKLTDYGMCKEGLGPGDTTstFCGTPNyIAPEILRGEEyGF |
| Q05655 | T507 | GPS6 | PRKCD PKCD | IKIADFGMCKENIFGEsRAstFCGtPDyIAPEILQGLKyTF |
| Q13153 | T423 | GPS6 | PAK1 | VKLTDFGFCAQITPEQSKRstMVGTPYWMAPEVVTRKAYGP |
| Q15118 | S27 | Sugiyama | PDK1 PDHK1 | LRGAALAGPGPGLRAAGFsRsFsSDSGSSPASERGVPGQVD |
| Q15118 | S29 | Sugiyama | PDK1 PDHK1 | GAALAGPGPGLRAAGFsRsFsSDSGSSPASERGVPGQVDFy |
| Q15118 | S396 | Sugiyama | PDK1 PDHK1 | YSLEGYGTDAVIYIKALsTDsIERLPVyNKAAWKHyNtNHE |
| Q15118 | S424 | Sugiyama | PDK1 PDHK1 | NKAAWKHyNtNHEADDWCVPsREPKDMTTFRSA________ |
| Q15118 | S67 | Sugiyama | PDK1 PDHK1 | DFyARFSPSPLSMKQFLDFGsVNACEKTSFMFLRQELPVRL |
| Q15118 | T413 | Sugiyama | PDK1 PDHK1 | sTDsIERLPVyNKAAWKHyNtNHEADDWCVPsREPKDMTTF |
| Q15118 | Y136 | Sugiyama | PDK1 PDHK1 | QSLQELLDFKDKSAEDAKAIyDFTDTVIRIRNRHNDVIPTM |
| Q15118 | Y368 | Sugiyama | PDK1 PDHK1 | RAVPLAGFGYGLPISRLYAQyFQGDLKLYSLEGYGTDAVIY |
| Q15118 | Y403 | Sugiyama | PDK1 PDHK1 | TDAVIYIKALsTDsIERLPVyNKAAWKHyNtNHEADDWCVP |
| Q15118 | Y411 | Sugiyama | PDK1 PDHK1 | ALsTDsIERLPVyNKAAWKHyNtNHEADDWCVPsREPKDMT |
| Q15118 | Y49 | Sugiyama | PDK1 PDHK1 | sSDSGSSPASERGVPGQVDFyARFSPSPLSMKQFLDFGsVN |
| Q15418 | S221 | GPS6 | RPS6KA1 MAPKAPK1A RSK1 | IKLTDFGLSKEAIDHEKKAysFCGtVEYMAPEVVNRQGHSH |
| Q16512 | T774 | GPS6 | PKN1 PAK1 PKN PRK1 PRKCL1 | VKIADFGLCKEGMGyGDRtstFCGtPEFLAPEVLTDTSYTR |
| Q16513 | S583 | Sugiyama | PKN2 PRK2 PRKCL2 | VTKLDFDLEPEPPPAPPRAssLGEIDEssELRVLDIPGQDs |
| Q16513 | T816 | GPS6 | PKN2 PRK2 PRKCL2 | VKIADFGLCKEGMGYGDRtstFCGtPEFLAPEVLTETSYTR |
| Q58FF6 | S34 | Sugiyama | HSP90AB4P | IFLQELISNASDALDKIRyEsLtDPsKLDGGKELKIDIIPN |
| Q58FF7 | S58 | Sugiyama | HSP90AB3P HSP90BC | IFLQELISNASDALDKIRyEsLtDPsKLDsGKELKIDIIPN |
| Q58FF8 | S58 | Sugiyama | HSP90AB2P HSP90BB | IFLWELISNASDALDKIRyEsLtDPsKLDsGKELKIDIIPN |
| Q6PEY2 | S48 | Sugiyama | TUBA3E | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q71U36 | S48 | Sugiyama | TUBA1A TUBA3 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q96BR1 | T320 | GPS6 | SGK3 CISK SGKL | VVLTDFGLCKEGIAISDTTTtFCGTPEYLAPEVIRKQPYDN |
| Q96HE7 | S143 | Sugiyama | ERO1A ERO1L UNQ434/PRO865 | EANNLIEECEQAERLGAVDEsLsEEtQKAVLQWTKHDDSSD |
| Q99683 | T838 | GPS6 | MAP3K5 ASK1 MAPKKK5 MEKK5 | LKISDFGtSKRLAGINPCTEtFTGtLQyMAPEIIDKGPRGY |
| Q9BQE3 | S48 | Sugiyama | TUBA1C TUBA6 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q9UPQ0 | S207 | Sugiyama | LIMCH1 KIAA1102 | RsDsLsPPRHGRDDsFDsLDsFGsRsRQtPsPDVVLRGssD |
| Q9Y243 | T305 | GPS6 | AKT3 PKBG | IKITDFGLCKEGITDAATMKtFCGtPEyLAPEVLEDNDyGR |
| Q9Y639 | Y220 | Sugiyama | NPTN SDFR1 SDR1 | NMEYRINKPRAEDsGEyHCVyHFVsAPKANATIEVKAAPDI |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.957176e-08 | 7.708 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 3.369650e-08 | 7.472 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.165647e-07 | 6.933 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 2.217760e-07 | 6.654 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 2.217760e-07 | 6.654 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.144073e-07 | 6.669 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 5.429025e-07 | 6.265 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 7.861205e-07 | 6.105 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.144945e-06 | 5.941 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.727993e-06 | 5.762 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 7.658644e-06 | 5.116 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 8.680470e-06 | 5.061 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.185925e-05 | 4.926 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.150563e-05 | 4.939 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.557850e-05 | 4.807 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.786213e-05 | 4.748 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 2.445658e-05 | 4.612 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 2.398813e-05 | 4.620 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 3.043725e-05 | 4.517 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.626400e-05 | 4.441 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 3.520219e-05 | 4.453 | 1 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 4.027820e-05 | 4.395 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 4.160396e-05 | 4.381 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 4.603215e-05 | 4.337 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 4.632181e-05 | 4.334 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 5.012072e-05 | 4.300 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 5.500854e-05 | 4.260 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 5.800585e-05 | 4.237 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 7.105875e-05 | 4.148 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 7.795873e-05 | 4.108 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 8.270413e-05 | 4.082 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 9.666049e-05 | 4.015 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.018705e-04 | 3.992 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.032838e-04 | 3.986 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.367821e-04 | 3.864 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.496676e-04 | 3.825 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.496676e-04 | 3.825 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.621981e-04 | 3.790 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.602783e-04 | 3.795 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.673392e-04 | 3.776 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 2.047449e-04 | 3.689 | 0 | 0 |
| Kinesins | R-HSA-983189 | 2.012336e-04 | 3.696 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 2.174386e-04 | 3.663 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 2.467279e-04 | 3.608 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 2.458195e-04 | 3.609 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.707256e-04 | 3.567 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 2.726498e-04 | 3.564 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 5.446398e-04 | 3.264 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 5.625573e-04 | 3.250 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 6.029934e-04 | 3.220 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 6.247118e-04 | 3.204 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 6.850869e-04 | 3.164 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 6.850869e-04 | 3.164 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.112223e-04 | 3.148 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 7.838014e-04 | 3.106 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 7.728455e-04 | 3.112 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 8.263520e-04 | 3.083 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 8.474978e-04 | 3.072 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 8.818693e-04 | 3.055 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.153520e-03 | 2.938 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.202434e-03 | 2.920 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.207556e-03 | 2.918 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.270493e-03 | 2.896 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.288316e-03 | 2.890 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.543419e-03 | 2.812 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.514186e-03 | 2.820 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.589966e-03 | 2.799 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.609012e-03 | 2.793 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.710998e-03 | 2.767 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.756343e-03 | 2.755 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 1.926949e-03 | 2.715 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 2.015933e-03 | 2.696 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 2.015933e-03 | 2.696 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 2.015933e-03 | 2.696 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.958804e-03 | 2.708 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 1.928661e-03 | 2.715 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 2.015933e-03 | 2.696 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.165822e-03 | 2.664 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 2.823565e-03 | 2.549 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 2.823565e-03 | 2.549 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.775665e-03 | 2.557 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 2.650304e-03 | 2.577 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.517167e-03 | 2.599 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 2.640225e-03 | 2.578 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.001468e-03 | 2.523 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.001468e-03 | 2.523 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 3.001468e-03 | 2.523 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 3.065302e-03 | 2.514 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 3.065302e-03 | 2.514 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 3.277657e-03 | 2.484 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 3.327159e-03 | 2.478 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 3.707190e-03 | 2.431 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 3.579047e-03 | 2.446 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 3.535010e-03 | 2.452 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 3.535010e-03 | 2.452 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 3.497698e-03 | 2.456 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.579047e-03 | 2.446 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 3.747832e-03 | 2.426 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 3.867588e-03 | 2.413 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 4.013301e-03 | 2.396 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 4.602948e-03 | 2.337 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 4.453510e-03 | 2.351 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 4.520406e-03 | 2.345 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 4.520406e-03 | 2.345 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 4.520406e-03 | 2.345 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 4.795652e-03 | 2.319 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 4.795652e-03 | 2.319 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 5.084299e-03 | 2.294 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 5.063268e-03 | 2.296 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 5.226137e-03 | 2.282 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 5.226137e-03 | 2.282 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 5.030886e-03 | 2.298 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 5.191779e-03 | 2.285 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 5.084299e-03 | 2.294 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 5.485082e-03 | 2.261 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 5.485082e-03 | 2.261 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 5.629484e-03 | 2.250 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 5.629484e-03 | 2.250 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 5.629484e-03 | 2.250 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 6.072216e-03 | 2.217 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 6.072216e-03 | 2.217 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 6.072216e-03 | 2.217 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 5.870561e-03 | 2.231 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 6.072216e-03 | 2.217 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 5.827608e-03 | 2.235 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 5.827608e-03 | 2.235 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 6.173900e-03 | 2.209 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 6.237430e-03 | 2.205 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 6.322357e-03 | 2.199 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 6.610748e-03 | 2.180 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 6.610748e-03 | 2.180 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 6.610748e-03 | 2.180 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 6.931628e-03 | 2.159 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 6.608663e-03 | 2.180 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 6.859364e-03 | 2.164 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 6.889636e-03 | 2.162 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 7.106172e-03 | 2.148 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 7.156732e-03 | 2.145 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 7.156732e-03 | 2.145 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 7.328663e-03 | 2.135 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 7.579616e-03 | 2.120 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 7.874564e-03 | 2.104 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 8.221029e-03 | 2.085 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 9.205981e-03 | 2.036 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 9.205981e-03 | 2.036 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 9.205981e-03 | 2.036 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 9.205981e-03 | 2.036 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 9.205981e-03 | 2.036 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 9.205981e-03 | 2.036 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 9.205981e-03 | 2.036 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 9.205981e-03 | 2.036 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 9.245463e-03 | 2.034 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 9.966749e-03 | 2.001 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 9.966749e-03 | 2.001 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 8.761917e-03 | 2.057 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 8.868154e-03 | 2.052 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 8.427850e-03 | 2.074 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 9.376185e-03 | 2.028 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 9.351262e-03 | 2.029 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 9.486781e-03 | 2.023 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 9.892572e-03 | 2.005 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.017792e-02 | 1.992 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.018773e-02 | 1.992 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.045347e-02 | 1.981 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 1.100562e-02 | 1.958 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.131804e-02 | 1.946 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.148438e-02 | 1.940 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.157127e-02 | 1.937 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 1.247788e-02 | 1.904 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 1.209079e-02 | 1.918 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 1.226266e-02 | 1.911 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.305391e-02 | 1.884 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.305391e-02 | 1.884 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.209079e-02 | 1.918 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.209237e-02 | 1.917 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 1.226266e-02 | 1.911 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 1.247788e-02 | 1.904 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.246711e-02 | 1.904 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.376206e-02 | 1.861 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 1.393631e-02 | 1.856 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.470227e-02 | 1.833 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.470227e-02 | 1.833 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.678658e-02 | 1.775 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 1.678658e-02 | 1.775 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 1.678658e-02 | 1.775 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 1.678658e-02 | 1.775 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 1.678658e-02 | 1.775 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 1.651304e-02 | 1.782 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 1.673380e-02 | 1.776 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 1.651304e-02 | 1.782 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.678658e-02 | 1.775 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.651636e-02 | 1.782 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.651636e-02 | 1.782 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.738444e-02 | 1.760 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.771477e-02 | 1.752 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 1.869865e-02 | 1.728 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 1.912332e-02 | 1.718 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 1.963119e-02 | 1.707 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 1.963119e-02 | 1.707 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 1.999976e-02 | 1.699 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 1.999976e-02 | 1.699 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 2.240709e-02 | 1.650 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 2.240709e-02 | 1.650 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 2.258383e-02 | 1.646 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 2.139302e-02 | 1.670 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 2.139302e-02 | 1.670 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 2.139302e-02 | 1.670 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.304732e-02 | 1.637 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.171057e-02 | 1.663 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.025317e-02 | 1.694 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.018557e-02 | 1.695 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 2.045141e-02 | 1.689 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 2.298612e-02 | 1.639 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.226536e-02 | 1.652 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 2.106651e-02 | 1.676 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 2.280950e-02 | 1.642 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 2.258383e-02 | 1.646 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 2.170577e-02 | 1.663 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 2.025317e-02 | 1.694 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 2.240709e-02 | 1.650 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.352448e-02 | 1.628 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 2.354360e-02 | 1.628 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.367422e-02 | 1.626 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 2.385189e-02 | 1.622 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 2.392427e-02 | 1.621 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 2.392427e-02 | 1.621 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 2.444731e-02 | 1.612 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 2.542857e-02 | 1.595 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 2.542857e-02 | 1.595 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 2.542857e-02 | 1.595 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 2.542857e-02 | 1.595 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.932630e-02 | 1.533 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 2.932630e-02 | 1.533 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 2.959470e-02 | 1.529 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 2.959470e-02 | 1.529 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 2.719218e-02 | 1.566 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.738350e-02 | 1.563 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 2.682038e-02 | 1.572 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 2.977254e-02 | 1.526 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 2.815067e-02 | 1.551 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 2.959470e-02 | 1.529 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 2.947753e-02 | 1.531 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 2.867815e-02 | 1.542 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 2.887260e-02 | 1.540 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 2.887260e-02 | 1.540 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 2.887260e-02 | 1.540 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 2.932630e-02 | 1.533 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 2.643811e-02 | 1.578 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.977254e-02 | 1.526 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 2.950436e-02 | 1.530 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 2.918186e-02 | 1.535 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 2.637388e-02 | 1.579 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 2.809416e-02 | 1.551 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 2.950436e-02 | 1.530 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 2.932630e-02 | 1.533 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 2.932630e-02 | 1.533 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.682038e-02 | 1.572 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.003442e-02 | 1.522 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 3.003442e-02 | 1.522 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 3.089200e-02 | 1.510 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 3.107935e-02 | 1.508 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 3.107935e-02 | 1.508 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 3.123987e-02 | 1.505 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 3.151889e-02 | 1.501 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 3.162888e-02 | 1.500 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 3.162888e-02 | 1.500 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 3.234944e-02 | 1.490 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 3.234944e-02 | 1.490 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 3.234944e-02 | 1.490 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.245790e-02 | 1.489 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 3.245790e-02 | 1.489 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.245790e-02 | 1.489 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 3.322254e-02 | 1.479 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 3.322254e-02 | 1.479 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 3.355131e-02 | 1.474 | 0 | 0 |
| Activation, translocation and oligomerization of BAX | R-HSA-114294 | 3.403425e-02 | 1.468 | 0 | 0 |
| Activation and oligomerization of BAK protein | R-HSA-111452 | 3.403425e-02 | 1.468 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 3.403425e-02 | 1.468 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 3.403425e-02 | 1.468 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 3.403425e-02 | 1.468 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 3.403425e-02 | 1.468 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 3.403425e-02 | 1.468 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 3.403425e-02 | 1.468 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 3.621081e-02 | 1.441 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 4.027035e-02 | 1.395 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 4.027035e-02 | 1.395 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 4.027035e-02 | 1.395 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 4.027035e-02 | 1.395 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 4.027035e-02 | 1.395 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 3.649445e-02 | 1.438 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 3.649445e-02 | 1.438 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 3.728771e-02 | 1.428 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 3.931132e-02 | 1.405 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.027035e-02 | 1.395 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 4.029417e-02 | 1.395 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 4.029417e-02 | 1.395 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 3.644081e-02 | 1.438 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 3.608555e-02 | 1.443 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 3.527352e-02 | 1.453 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.761478e-02 | 1.425 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 3.761478e-02 | 1.425 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.595758e-02 | 1.444 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 3.653455e-02 | 1.437 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 3.391804e-02 | 1.470 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 3.457488e-02 | 1.461 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 3.762190e-02 | 1.425 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 4.082517e-02 | 1.389 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 4.115332e-02 | 1.386 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 4.115332e-02 | 1.386 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 4.115332e-02 | 1.386 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 4.115332e-02 | 1.386 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 4.179849e-02 | 1.379 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 4.210670e-02 | 1.376 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 4.210670e-02 | 1.376 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 4.210670e-02 | 1.376 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 4.210670e-02 | 1.376 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 4.219879e-02 | 1.375 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 4.223120e-02 | 1.374 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 4.224174e-02 | 1.374 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.296702e-02 | 1.367 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 4.333362e-02 | 1.363 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 4.370792e-02 | 1.359 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 4.406258e-02 | 1.356 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 4.410877e-02 | 1.355 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 4.410877e-02 | 1.355 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 4.432969e-02 | 1.353 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 4.479270e-02 | 1.349 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 4.555623e-02 | 1.341 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 5.645262e-02 | 1.248 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 5.645262e-02 | 1.248 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 5.645262e-02 | 1.248 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 5.645262e-02 | 1.248 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 5.645262e-02 | 1.248 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 5.645262e-02 | 1.248 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 5.645262e-02 | 1.248 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 5.756463e-02 | 1.240 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 5.070308e-02 | 1.295 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 5.070308e-02 | 1.295 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 5.070308e-02 | 1.295 | 0 | 0 |
| PKA activation | R-HSA-163615 | 5.070308e-02 | 1.295 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 5.070308e-02 | 1.295 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 5.186962e-02 | 1.285 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 5.425913e-02 | 1.266 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 5.425913e-02 | 1.266 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 5.816596e-02 | 1.235 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 5.526529e-02 | 1.258 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 5.810213e-02 | 1.236 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 5.810213e-02 | 1.236 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.369028e-02 | 1.270 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 5.661311e-02 | 1.247 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 5.576239e-02 | 1.254 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 5.648313e-02 | 1.248 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 4.966422e-02 | 1.304 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 4.713961e-02 | 1.327 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 5.186962e-02 | 1.285 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.959653e-02 | 1.305 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.959653e-02 | 1.305 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 4.796802e-02 | 1.319 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 5.070308e-02 | 1.295 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 5.242270e-02 | 1.280 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 4.961451e-02 | 1.304 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 5.076262e-02 | 1.294 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 4.851053e-02 | 1.314 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 5.070308e-02 | 1.295 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 5.070308e-02 | 1.295 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 5.847293e-02 | 1.233 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 5.847293e-02 | 1.233 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 5.847293e-02 | 1.233 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 5.847293e-02 | 1.233 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 5.860259e-02 | 1.232 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 5.860259e-02 | 1.232 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 5.877818e-02 | 1.231 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 6.027669e-02 | 1.220 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 6.034376e-02 | 1.219 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 6.049623e-02 | 1.218 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 6.071971e-02 | 1.217 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 6.122643e-02 | 1.213 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 6.122643e-02 | 1.213 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 6.139507e-02 | 1.212 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 6.140864e-02 | 1.212 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 6.144431e-02 | 1.212 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 6.719755e-02 | 1.173 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 6.807163e-02 | 1.167 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 6.840393e-02 | 1.165 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 6.910249e-02 | 1.161 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 6.910249e-02 | 1.161 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 6.926637e-02 | 1.159 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.940664e-02 | 1.159 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 6.940664e-02 | 1.159 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.970648e-02 | 1.157 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 6.980422e-02 | 1.156 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 6.980422e-02 | 1.156 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 6.980422e-02 | 1.156 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 6.980422e-02 | 1.156 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 6.993369e-02 | 1.155 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 7.105801e-02 | 1.148 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 7.105801e-02 | 1.148 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 7.105801e-02 | 1.148 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 8.094804e-02 | 1.092 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 8.094804e-02 | 1.092 | 0 | 0 |
| IRS activation | R-HSA-74713 | 8.094804e-02 | 1.092 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 8.094804e-02 | 1.092 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 8.094804e-02 | 1.092 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 7.564810e-02 | 1.121 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 7.564810e-02 | 1.121 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 7.564810e-02 | 1.121 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 7.564810e-02 | 1.121 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 8.297903e-02 | 1.081 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 8.297903e-02 | 1.081 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 8.297903e-02 | 1.081 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 8.491727e-02 | 1.071 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 8.491727e-02 | 1.071 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 7.186546e-02 | 1.143 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 8.414418e-02 | 1.075 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 7.558699e-02 | 1.122 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 7.558699e-02 | 1.122 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 7.558699e-02 | 1.122 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 7.558699e-02 | 1.122 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 8.270165e-02 | 1.082 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 8.118169e-02 | 1.091 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 9.546557e-02 | 1.020 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 8.464110e-02 | 1.072 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 9.053116e-02 | 1.043 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 7.345698e-02 | 1.134 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 7.616406e-02 | 1.118 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 8.512079e-02 | 1.070 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 7.204154e-02 | 1.142 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 7.970423e-02 | 1.099 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 8.193501e-02 | 1.087 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 8.414418e-02 | 1.075 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 7.204154e-02 | 1.142 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 7.223132e-02 | 1.141 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 8.636041e-02 | 1.064 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 8.297903e-02 | 1.081 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 9.384382e-02 | 1.028 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 7.959326e-02 | 1.099 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 9.273564e-02 | 1.033 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 8.520092e-02 | 1.070 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 7.959326e-02 | 1.099 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 7.214100e-02 | 1.142 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 8.212814e-02 | 1.086 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 7.186546e-02 | 1.143 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 8.920137e-02 | 1.050 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 8.953113e-02 | 1.048 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 7.186546e-02 | 1.143 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 8.839954e-02 | 1.054 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 7.564810e-02 | 1.121 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 9.391558e-02 | 1.027 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 8.495722e-02 | 1.071 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 8.497500e-02 | 1.071 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 7.515534e-02 | 1.124 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 9.391558e-02 | 1.027 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 8.243492e-02 | 1.084 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 7.564810e-02 | 1.121 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 9.552364e-02 | 1.020 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 9.623375e-02 | 1.017 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 9.623375e-02 | 1.017 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 9.623375e-02 | 1.017 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 9.623375e-02 | 1.017 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 9.623375e-02 | 1.017 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 9.623375e-02 | 1.017 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 9.623375e-02 | 1.017 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 9.630880e-02 | 1.016 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 9.754670e-02 | 1.011 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 9.754670e-02 | 1.011 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 9.754670e-02 | 1.011 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.754670e-02 | 1.011 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 9.788589e-02 | 1.009 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 1.000572e-01 | 1.000 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.005393e-01 | 0.998 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 1.005393e-01 | 0.998 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 1.005393e-01 | 0.998 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.005393e-01 | 0.998 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.005393e-01 | 0.998 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.010986e-01 | 0.995 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.023098e-01 | 0.990 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 1.031667e-01 | 0.986 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 1.035315e-01 | 0.985 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.037793e-01 | 0.984 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.051784e-01 | 0.978 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.335873e-01 | 0.874 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.335873e-01 | 0.874 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.335873e-01 | 0.874 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.335873e-01 | 0.874 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.335873e-01 | 0.874 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.335873e-01 | 0.874 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.335873e-01 | 0.874 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.335873e-01 | 0.874 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.335873e-01 | 0.874 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.335873e-01 | 0.874 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 1.335873e-01 | 0.874 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.335873e-01 | 0.874 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.335873e-01 | 0.874 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.335873e-01 | 0.874 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.335873e-01 | 0.874 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.335873e-01 | 0.874 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.335873e-01 | 0.874 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.335873e-01 | 0.874 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.335873e-01 | 0.874 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.335873e-01 | 0.874 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 1.335873e-01 | 0.874 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.335873e-01 | 0.874 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 1.335873e-01 | 0.874 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.132563e-01 | 0.946 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.132563e-01 | 0.946 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 1.132563e-01 | 0.946 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.132563e-01 | 0.946 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 1.132563e-01 | 0.946 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 1.132563e-01 | 0.946 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.132563e-01 | 0.946 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.132563e-01 | 0.946 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.132563e-01 | 0.946 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.132563e-01 | 0.946 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.132563e-01 | 0.946 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.132563e-01 | 0.946 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.132563e-01 | 0.946 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.132563e-01 | 0.946 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.132563e-01 | 0.946 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 1.092073e-01 | 0.962 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 1.092073e-01 | 0.962 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 1.092073e-01 | 0.962 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 1.092073e-01 | 0.962 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 1.092073e-01 | 0.962 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 1.092073e-01 | 0.962 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.406611e-01 | 0.852 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 1.406611e-01 | 0.852 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 1.191409e-01 | 0.924 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.191409e-01 | 0.924 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.406309e-01 | 0.852 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 1.406309e-01 | 0.852 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.406309e-01 | 0.852 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.536356e-01 | 0.814 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.133725e-01 | 0.945 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.264308e-01 | 0.898 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 1.264308e-01 | 0.898 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.506043e-01 | 0.822 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 1.402524e-01 | 0.853 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.306914e-01 | 0.884 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.137101e-01 | 0.944 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 1.437725e-01 | 0.842 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.437725e-01 | 0.842 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 1.437725e-01 | 0.842 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.081488e-01 | 0.966 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.081488e-01 | 0.966 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 1.591001e-01 | 0.798 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 1.475509e-01 | 0.831 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 1.485814e-01 | 0.828 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 1.318267e-01 | 0.880 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.486515e-01 | 0.828 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.535188e-01 | 0.814 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.591814e-01 | 0.798 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.065522e-01 | 0.972 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 1.437725e-01 | 0.842 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 1.406611e-01 | 0.852 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.191409e-01 | 0.924 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 1.461042e-01 | 0.835 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.461042e-01 | 0.835 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.558472e-01 | 0.807 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.370442e-01 | 0.863 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 1.120513e-01 | 0.951 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 1.105946e-01 | 0.956 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 1.197936e-01 | 0.922 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 1.120513e-01 | 0.951 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.354475e-01 | 0.868 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 1.218639e-01 | 0.914 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.361177e-01 | 0.866 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 1.406611e-01 | 0.852 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.282659e-01 | 0.892 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.402524e-01 | 0.853 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 1.437725e-01 | 0.842 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 1.437725e-01 | 0.842 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.218639e-01 | 0.914 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.182789e-01 | 0.927 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 1.426848e-01 | 0.846 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 1.061724e-01 | 0.974 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.461042e-01 | 0.835 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 1.092073e-01 | 0.962 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.167314e-01 | 0.933 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 1.196894e-01 | 0.922 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 1.344097e-01 | 0.872 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.274508e-01 | 0.895 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 1.567847e-01 | 0.805 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 1.350978e-01 | 0.869 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 1.274508e-01 | 0.895 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 1.092073e-01 | 0.962 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 1.406611e-01 | 0.852 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.221881e-01 | 0.913 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 1.336863e-01 | 0.874 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 1.336863e-01 | 0.874 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.345829e-01 | 0.871 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 1.186798e-01 | 0.926 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.406309e-01 | 0.852 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.132563e-01 | 0.946 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.061724e-01 | 0.974 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 1.437725e-01 | 0.842 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 1.106507e-01 | 0.956 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 1.191409e-01 | 0.924 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 1.276245e-01 | 0.894 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 1.442217e-01 | 0.841 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.515991e-01 | 0.819 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.244457e-01 | 0.905 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 1.441455e-01 | 0.841 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.276245e-01 | 0.894 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.191409e-01 | 0.924 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.367005e-01 | 0.864 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.336863e-01 | 0.874 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 1.120513e-01 | 0.951 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.486470e-01 | 0.828 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.582730e-01 | 0.801 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.598947e-01 | 0.796 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.599864e-01 | 0.796 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 1.600872e-01 | 0.796 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 1.617015e-01 | 0.791 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 1.617015e-01 | 0.791 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 1.617015e-01 | 0.791 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 1.617015e-01 | 0.791 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 1.617015e-01 | 0.791 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.629192e-01 | 0.788 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.629192e-01 | 0.788 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.629192e-01 | 0.788 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 1.629192e-01 | 0.788 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 1.629192e-01 | 0.788 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.669259e-01 | 0.777 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 1.669259e-01 | 0.777 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.669259e-01 | 0.777 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 1.669259e-01 | 0.777 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.686341e-01 | 0.773 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 1.700737e-01 | 0.769 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 1.709930e-01 | 0.767 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.709930e-01 | 0.767 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.714691e-01 | 0.766 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 1.718512e-01 | 0.765 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 1.718512e-01 | 0.765 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 1.718512e-01 | 0.765 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 1.726535e-01 | 0.763 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 1.738013e-01 | 0.760 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 1.738013e-01 | 0.760 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 1.738013e-01 | 0.760 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.738013e-01 | 0.760 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.738013e-01 | 0.760 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.738013e-01 | 0.760 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.747084e-01 | 0.758 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 1.747084e-01 | 0.758 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.747084e-01 | 0.758 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.747084e-01 | 0.758 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 1.747084e-01 | 0.758 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 1.747084e-01 | 0.758 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.747084e-01 | 0.758 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.758120e-01 | 0.755 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.762843e-01 | 0.754 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.789258e-01 | 0.747 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.793782e-01 | 0.746 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 1.802623e-01 | 0.744 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 1.802623e-01 | 0.744 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.493357e-01 | 0.603 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 2.493357e-01 | 0.603 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 2.493357e-01 | 0.603 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 2.493357e-01 | 0.603 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.493357e-01 | 0.603 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.493357e-01 | 0.603 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 2.493357e-01 | 0.603 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 2.493357e-01 | 0.603 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 2.493357e-01 | 0.603 | 0 | 0 |
| Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR) | R-HSA-5619110 | 2.493357e-01 | 0.603 | 0 | 0 |
| Defective SLC33A1 causes spastic paraplegia 42 (SPG42) | R-HSA-5619061 | 2.493357e-01 | 0.603 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.493357e-01 | 0.603 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 2.493357e-01 | 0.603 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.493357e-01 | 0.603 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 2.130315e-01 | 0.672 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 2.130315e-01 | 0.672 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 2.130315e-01 | 0.672 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 2.130315e-01 | 0.672 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 3.496264e-01 | 0.456 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 3.496264e-01 | 0.456 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 3.496264e-01 | 0.456 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective GALE causes EDG | R-HSA-5609977 | 3.496264e-01 | 0.456 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 3.496264e-01 | 0.456 | 0 | 0 |
| XAV939 stabilizes AXIN | R-HSA-5545619 | 3.496264e-01 | 0.456 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 3.496264e-01 | 0.456 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective APRT disrupts adenine salvage | R-HSA-9734195 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome | R-HSA-5678420 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 3.496264e-01 | 0.456 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 3.496264e-01 | 0.456 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 3.496264e-01 | 0.456 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 3.496264e-01 | 0.456 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) | R-HSA-5619048 | 3.496264e-01 | 0.456 | 0 | 0 |
| Defective SLC12A3 causes Gitelman syndrome (GS) | R-HSA-5619087 | 3.496264e-01 | 0.456 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 2.656121e-01 | 0.576 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 2.656121e-01 | 0.576 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 2.656121e-01 | 0.576 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 2.656121e-01 | 0.576 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 2.656121e-01 | 0.576 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 2.656121e-01 | 0.576 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 2.656121e-01 | 0.576 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 2.656121e-01 | 0.576 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 2.656121e-01 | 0.576 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 2.656121e-01 | 0.576 | 0 | 0 |
| RSK activation | R-HSA-444257 | 2.107509e-01 | 0.676 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 2.107509e-01 | 0.676 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 1.994098e-01 | 0.700 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.994098e-01 | 0.700 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.994098e-01 | 0.700 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 1.994098e-01 | 0.700 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 1.994098e-01 | 0.700 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 1.994098e-01 | 0.700 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.994098e-01 | 0.700 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 2.482161e-01 | 0.605 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 2.482161e-01 | 0.605 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 2.482161e-01 | 0.605 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 2.482161e-01 | 0.605 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 3.181937e-01 | 0.497 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 3.181937e-01 | 0.497 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 3.181937e-01 | 0.497 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 3.181937e-01 | 0.497 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 3.181937e-01 | 0.497 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 3.181937e-01 | 0.497 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 3.181937e-01 | 0.497 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 1.865096e-01 | 0.729 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.865096e-01 | 0.729 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 1.865096e-01 | 0.729 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 2.291137e-01 | 0.640 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 2.112414e-01 | 0.675 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.112414e-01 | 0.675 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.949814e-01 | 0.710 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 2.598219e-01 | 0.585 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.369459e-01 | 0.625 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 2.369459e-01 | 0.625 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 3.253415e-01 | 0.488 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.995722e-01 | 0.700 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 2.912581e-01 | 0.536 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 2.399503e-01 | 0.620 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 2.018197e-01 | 0.695 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 2.018197e-01 | 0.695 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.867942e-01 | 0.729 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 2.403889e-01 | 0.619 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.635089e-01 | 0.579 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 2.635089e-01 | 0.579 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.635089e-01 | 0.579 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 2.905835e-01 | 0.537 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 2.022972e-01 | 0.694 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 2.617291e-01 | 0.582 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 2.617291e-01 | 0.582 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 2.617291e-01 | 0.582 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 2.589272e-01 | 0.587 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 3.552740e-01 | 0.449 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 2.348370e-01 | 0.629 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 2.517944e-01 | 0.599 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 3.460578e-01 | 0.461 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 2.088641e-01 | 0.680 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 1.913897e-01 | 0.718 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 2.478571e-01 | 0.606 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 2.478571e-01 | 0.606 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 2.994273e-01 | 0.524 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 2.692294e-01 | 0.570 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.636976e-01 | 0.579 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 3.412312e-01 | 0.467 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 3.516672e-01 | 0.454 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 2.682610e-01 | 0.571 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 2.193011e-01 | 0.659 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 2.864856e-01 | 0.543 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 2.393388e-01 | 0.621 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 2.048664e-01 | 0.689 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 1.994098e-01 | 0.700 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 2.583353e-01 | 0.588 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 2.531366e-01 | 0.597 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 3.552740e-01 | 0.449 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 3.121802e-01 | 0.506 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 2.865731e-01 | 0.543 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 2.112414e-01 | 0.675 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.867405e-01 | 0.729 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.857151e-01 | 0.731 | 0 | 0 |
| Protein folding | R-HSA-391251 | 2.196536e-01 | 0.658 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 3.231582e-01 | 0.491 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 2.617291e-01 | 0.582 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 3.121802e-01 | 0.506 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 2.373767e-01 | 0.625 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 2.399503e-01 | 0.620 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 2.018197e-01 | 0.695 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 2.403889e-01 | 0.619 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 2.994273e-01 | 0.524 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 2.369459e-01 | 0.625 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 1.860048e-01 | 0.730 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 2.221503e-01 | 0.653 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 2.107509e-01 | 0.676 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 2.291137e-01 | 0.640 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 2.876253e-01 | 0.541 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 3.552740e-01 | 0.449 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 2.930839e-01 | 0.533 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 3.417061e-01 | 0.466 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 2.130315e-01 | 0.672 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 2.865731e-01 | 0.543 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 1.840153e-01 | 0.735 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.876253e-01 | 0.541 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.876253e-01 | 0.541 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 2.589272e-01 | 0.587 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.164068e-01 | 0.665 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 2.789796e-01 | 0.554 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 2.989836e-01 | 0.524 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 3.319132e-01 | 0.479 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 2.373767e-01 | 0.625 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 2.373767e-01 | 0.625 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 3.284267e-01 | 0.484 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 2.589272e-01 | 0.587 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 2.202814e-01 | 0.657 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 2.467174e-01 | 0.608 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 2.369459e-01 | 0.625 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 2.635089e-01 | 0.579 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 1.995722e-01 | 0.700 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.384557e-01 | 0.623 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 2.634508e-01 | 0.579 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 3.640963e-01 | 0.439 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 3.552740e-01 | 0.449 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 3.603913e-01 | 0.443 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.160128e-01 | 0.500 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 3.253415e-01 | 0.488 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 2.617291e-01 | 0.582 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 2.876253e-01 | 0.541 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 3.123667e-01 | 0.505 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 2.072719e-01 | 0.683 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 2.682610e-01 | 0.571 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 2.865731e-01 | 0.543 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 2.781530e-01 | 0.556 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.923969e-01 | 0.716 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 2.741211e-01 | 0.562 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 2.013347e-01 | 0.696 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 2.013347e-01 | 0.696 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 2.028430e-01 | 0.693 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 2.130315e-01 | 0.672 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 2.656121e-01 | 0.576 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 2.482161e-01 | 0.605 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 3.181937e-01 | 0.497 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 3.181937e-01 | 0.497 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 2.112414e-01 | 0.675 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.112414e-01 | 0.675 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 2.598219e-01 | 0.585 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 3.640963e-01 | 0.439 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 3.512564e-01 | 0.454 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 2.355425e-01 | 0.628 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 3.185721e-01 | 0.497 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 2.741211e-01 | 0.562 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 2.141203e-01 | 0.669 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 2.553508e-01 | 0.593 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.197027e-01 | 0.658 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 3.474604e-01 | 0.459 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.031210e-01 | 0.692 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 3.181937e-01 | 0.497 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 2.170688e-01 | 0.663 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 3.253415e-01 | 0.488 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 3.460578e-01 | 0.461 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 2.356379e-01 | 0.628 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.986120e-01 | 0.525 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 3.237349e-01 | 0.490 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 2.656121e-01 | 0.576 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 2.865731e-01 | 0.543 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 3.181741e-01 | 0.497 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.284267e-01 | 0.484 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 3.571938e-01 | 0.447 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 2.932129e-01 | 0.533 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 2.555338e-01 | 0.593 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 2.517944e-01 | 0.599 | 1 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 2.813015e-01 | 0.551 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 3.072297e-01 | 0.513 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 2.622549e-01 | 0.581 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 2.493357e-01 | 0.603 | 0 | 0 |
| SDK interactions | R-HSA-373756 | 2.493357e-01 | 0.603 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 3.496264e-01 | 0.456 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 3.496264e-01 | 0.456 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 2.656121e-01 | 0.576 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 2.482161e-01 | 0.605 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 3.181937e-01 | 0.497 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 2.994273e-01 | 0.524 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 2.808165e-01 | 0.552 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 1.925023e-01 | 0.716 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 3.417061e-01 | 0.466 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 2.399503e-01 | 0.620 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.960237e-01 | 0.708 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 3.441625e-01 | 0.463 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.186748e-01 | 0.660 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 1.840153e-01 | 0.735 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 3.552740e-01 | 0.449 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 2.373767e-01 | 0.625 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 2.018197e-01 | 0.695 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 3.293159e-01 | 0.482 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 3.636419e-01 | 0.439 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 2.930839e-01 | 0.533 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 3.380086e-01 | 0.471 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 2.482161e-01 | 0.605 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 3.181937e-01 | 0.497 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 2.112414e-01 | 0.675 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 2.202814e-01 | 0.657 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 3.640963e-01 | 0.439 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 3.512564e-01 | 0.454 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 2.681748e-01 | 0.572 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.193011e-01 | 0.659 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.193011e-01 | 0.659 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.235672e-01 | 0.651 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 3.516672e-01 | 0.454 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 3.516672e-01 | 0.454 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 2.853864e-01 | 0.545 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 2.570915e-01 | 0.590 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.496264e-01 | 0.456 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 3.181937e-01 | 0.497 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 3.181937e-01 | 0.497 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.634508e-01 | 0.579 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 2.373767e-01 | 0.625 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.460578e-01 | 0.461 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 2.635089e-01 | 0.579 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 3.460578e-01 | 0.461 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 3.121802e-01 | 0.506 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 2.620502e-01 | 0.582 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.865096e-01 | 0.729 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.873884e-01 | 0.542 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 3.181741e-01 | 0.497 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 3.123667e-01 | 0.505 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 3.412312e-01 | 0.467 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 3.496264e-01 | 0.456 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 2.656121e-01 | 0.576 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 2.656121e-01 | 0.576 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 2.403889e-01 | 0.619 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 3.624489e-01 | 0.441 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 2.598219e-01 | 0.585 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 2.912581e-01 | 0.536 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 3.202010e-01 | 0.495 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 3.412312e-01 | 0.467 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 3.231582e-01 | 0.491 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 3.678303e-01 | 0.434 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 3.678303e-01 | 0.434 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 3.682079e-01 | 0.434 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 3.698380e-01 | 0.432 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 3.698380e-01 | 0.432 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 3.698380e-01 | 0.432 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.715729e-01 | 0.430 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 3.740773e-01 | 0.427 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 3.742396e-01 | 0.427 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 3.742396e-01 | 0.427 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 3.742396e-01 | 0.427 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 3.837866e-01 | 0.416 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 3.837866e-01 | 0.416 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 3.837866e-01 | 0.416 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.837866e-01 | 0.416 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 3.837866e-01 | 0.416 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 3.873118e-01 | 0.412 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.873118e-01 | 0.412 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 3.873765e-01 | 0.412 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 3.873765e-01 | 0.412 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 3.873765e-01 | 0.412 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 3.873765e-01 | 0.412 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 3.963020e-01 | 0.402 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 3.972927e-01 | 0.401 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 3.972927e-01 | 0.401 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 4.024695e-01 | 0.395 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 4.024695e-01 | 0.395 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.024695e-01 | 0.395 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 4.024695e-01 | 0.395 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 4.024695e-01 | 0.395 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.036562e-01 | 0.394 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 4.036562e-01 | 0.394 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 4.051782e-01 | 0.392 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 4.051782e-01 | 0.392 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 4.056691e-01 | 0.392 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 4.084813e-01 | 0.389 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.084813e-01 | 0.389 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 4.124757e-01 | 0.385 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 4.124757e-01 | 0.385 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 4.124757e-01 | 0.385 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 4.140665e-01 | 0.383 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 4.155387e-01 | 0.381 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 4.164882e-01 | 0.380 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 4.170185e-01 | 0.380 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 4.178974e-01 | 0.379 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 4.192574e-01 | 0.378 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 4.192574e-01 | 0.378 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 4.198573e-01 | 0.377 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 4.198573e-01 | 0.377 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 4.198573e-01 | 0.377 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 4.198573e-01 | 0.377 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 4.198573e-01 | 0.377 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 4.198573e-01 | 0.377 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 4.198573e-01 | 0.377 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 4.198573e-01 | 0.377 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 4.198573e-01 | 0.377 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 4.198573e-01 | 0.377 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 4.198573e-01 | 0.377 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 4.198573e-01 | 0.377 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 4.198573e-01 | 0.377 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 4.198658e-01 | 0.377 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 4.203352e-01 | 0.376 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 4.241556e-01 | 0.372 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 4.261841e-01 | 0.370 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 4.299415e-01 | 0.367 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 4.311468e-01 | 0.365 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 4.365231e-01 | 0.360 | 0 | 0 |
| Defective PAPSS2 causes SEMD-PA | R-HSA-3560796 | 4.365231e-01 | 0.360 | 0 | 0 |
| Defective UGT1A4 causes hyperbilirubinemia | R-HSA-5579016 | 4.365231e-01 | 0.360 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 4.365231e-01 | 0.360 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 4.365231e-01 | 0.360 | 0 | 0 |
| Defective visual phototransduction due to STRA6 loss of function | R-HSA-9918449 | 4.365231e-01 | 0.360 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 4.365231e-01 | 0.360 | 0 | 0 |
| Defective SLC12A1 causes Bartter syndrome 1 (BS1) | R-HSA-5619104 | 4.365231e-01 | 0.360 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 4.365231e-01 | 0.360 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 4.365231e-01 | 0.360 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 4.365231e-01 | 0.360 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 4.365231e-01 | 0.360 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 4.365231e-01 | 0.360 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 4.365231e-01 | 0.360 | 0 | 0 |
| Defective ABCC8 can cause hypo- and hyper-glycemias | R-HSA-5683177 | 4.365231e-01 | 0.360 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 4.365231e-01 | 0.360 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 4.365231e-01 | 0.360 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 4.370579e-01 | 0.359 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 4.375284e-01 | 0.359 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 4.375284e-01 | 0.359 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 4.401487e-01 | 0.356 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 4.401487e-01 | 0.356 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 4.401487e-01 | 0.356 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 4.401487e-01 | 0.356 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 4.401487e-01 | 0.356 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 4.401487e-01 | 0.356 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 4.401487e-01 | 0.356 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 4.401487e-01 | 0.356 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 4.401487e-01 | 0.356 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 4.427856e-01 | 0.354 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 4.507309e-01 | 0.346 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.507309e-01 | 0.346 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 4.507309e-01 | 0.346 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 4.507309e-01 | 0.346 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 4.507309e-01 | 0.346 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 4.516328e-01 | 0.345 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 4.542413e-01 | 0.343 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 4.548009e-01 | 0.342 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 4.575213e-01 | 0.340 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 4.575213e-01 | 0.340 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 4.575218e-01 | 0.340 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 4.660865e-01 | 0.332 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 4.670832e-01 | 0.331 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 4.677641e-01 | 0.330 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 4.677641e-01 | 0.330 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 4.677641e-01 | 0.330 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 4.677641e-01 | 0.330 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 4.677641e-01 | 0.330 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 4.677641e-01 | 0.330 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 4.677641e-01 | 0.330 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 4.677641e-01 | 0.330 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 4.690521e-01 | 0.329 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 4.735748e-01 | 0.325 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.753642e-01 | 0.323 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 4.768746e-01 | 0.322 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 4.768746e-01 | 0.322 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 4.768746e-01 | 0.322 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 4.768746e-01 | 0.322 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 4.768746e-01 | 0.322 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 4.768746e-01 | 0.322 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 4.768746e-01 | 0.322 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 4.769327e-01 | 0.322 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 4.788560e-01 | 0.320 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 4.816334e-01 | 0.317 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 4.816334e-01 | 0.317 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 4.816334e-01 | 0.317 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 4.816334e-01 | 0.317 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 4.816334e-01 | 0.317 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 4.816334e-01 | 0.317 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 4.835623e-01 | 0.316 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 4.839503e-01 | 0.315 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 4.847106e-01 | 0.315 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 4.847106e-01 | 0.315 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 4.869346e-01 | 0.313 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 4.886555e-01 | 0.311 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.900495e-01 | 0.310 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 4.900495e-01 | 0.310 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 4.900495e-01 | 0.310 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 4.900495e-01 | 0.310 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 4.912165e-01 | 0.309 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 4.931552e-01 | 0.307 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 4.938718e-01 | 0.306 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.945714e-01 | 0.306 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 4.957897e-01 | 0.305 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 4.981465e-01 | 0.303 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 4.999255e-01 | 0.301 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 5.106934e-01 | 0.292 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 5.107380e-01 | 0.292 | 1 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 5.108114e-01 | 0.292 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 5.109348e-01 | 0.292 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 5.114053e-01 | 0.291 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 5.114053e-01 | 0.291 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 5.114053e-01 | 0.291 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 5.114053e-01 | 0.291 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 5.114053e-01 | 0.291 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 5.114053e-01 | 0.291 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 5.114053e-01 | 0.291 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 5.114053e-01 | 0.291 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 5.118138e-01 | 0.291 | 0 | 0 |
| Defective DPM1 causes DPM1-CDG | R-HSA-4717374 | 5.118138e-01 | 0.291 | 0 | 0 |
| Defective DPM2 causes DPM2-CDG | R-HSA-4719377 | 5.118138e-01 | 0.291 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 5.118138e-01 | 0.291 | 0 | 0 |
| Defective DPM3 causes DPM3-CDG | R-HSA-4719360 | 5.118138e-01 | 0.291 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 5.118138e-01 | 0.291 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 5.118138e-01 | 0.291 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 5.118234e-01 | 0.291 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 5.118234e-01 | 0.291 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 5.118234e-01 | 0.291 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 5.119289e-01 | 0.291 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 5.124375e-01 | 0.290 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 5.124375e-01 | 0.290 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 5.124375e-01 | 0.290 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 5.124375e-01 | 0.290 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 5.124375e-01 | 0.290 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 5.124375e-01 | 0.290 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 5.124375e-01 | 0.290 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 5.124375e-01 | 0.290 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 5.124375e-01 | 0.290 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 5.132301e-01 | 0.290 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 5.132301e-01 | 0.290 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 5.132301e-01 | 0.290 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 5.132301e-01 | 0.290 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 5.132301e-01 | 0.290 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 5.132301e-01 | 0.290 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 5.132301e-01 | 0.290 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 5.132301e-01 | 0.290 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 5.132301e-01 | 0.290 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 5.132301e-01 | 0.290 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 5.132301e-01 | 0.290 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 5.225373e-01 | 0.282 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 5.248640e-01 | 0.280 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 5.248640e-01 | 0.280 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 5.256624e-01 | 0.279 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 5.300894e-01 | 0.276 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 5.328670e-01 | 0.273 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 5.348724e-01 | 0.272 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 5.367656e-01 | 0.270 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 5.367656e-01 | 0.270 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 5.367656e-01 | 0.270 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 5.375157e-01 | 0.270 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 5.375157e-01 | 0.270 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 5.375157e-01 | 0.270 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 5.411814e-01 | 0.267 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 5.432203e-01 | 0.265 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 5.466729e-01 | 0.262 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 5.466729e-01 | 0.262 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 5.466729e-01 | 0.262 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 5.466729e-01 | 0.262 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 5.466729e-01 | 0.262 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 5.470048e-01 | 0.262 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 5.514417e-01 | 0.259 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 5.524676e-01 | 0.258 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 5.531024e-01 | 0.257 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 5.544001e-01 | 0.256 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 5.560523e-01 | 0.255 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 5.560523e-01 | 0.255 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 5.560523e-01 | 0.255 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 5.560523e-01 | 0.255 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 5.560523e-01 | 0.255 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 5.560523e-01 | 0.255 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 5.560523e-01 | 0.255 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 5.560523e-01 | 0.255 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 5.560523e-01 | 0.255 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 5.560523e-01 | 0.255 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 5.560523e-01 | 0.255 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 5.560523e-01 | 0.255 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 5.560523e-01 | 0.255 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 5.629633e-01 | 0.250 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 5.632703e-01 | 0.249 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 5.660701e-01 | 0.247 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 5.674018e-01 | 0.246 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 5.696081e-01 | 0.244 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 5.696081e-01 | 0.244 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 5.754872e-01 | 0.240 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 5.770481e-01 | 0.239 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 5.770481e-01 | 0.239 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 5.770481e-01 | 0.239 | 0 | 0 |
| Defective FMO3 causes TMAU | R-HSA-5579019 | 5.770481e-01 | 0.239 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 5.770481e-01 | 0.239 | 0 | 0 |
| Signaling by LRP5 mutants | R-HSA-5339717 | 5.770481e-01 | 0.239 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 5.770481e-01 | 0.239 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 5.770481e-01 | 0.239 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 5.770481e-01 | 0.239 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 5.770481e-01 | 0.239 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 5.770481e-01 | 0.239 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 5.770481e-01 | 0.239 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 5.770481e-01 | 0.239 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 5.770481e-01 | 0.239 | 0 | 0 |
| GABA synthesis | R-HSA-888568 | 5.770481e-01 | 0.239 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 5.770481e-01 | 0.239 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 5.770481e-01 | 0.239 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 5.770481e-01 | 0.239 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 5.770481e-01 | 0.239 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 5.789832e-01 | 0.237 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 5.811770e-01 | 0.236 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 5.876815e-01 | 0.231 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 5.876815e-01 | 0.231 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 5.877780e-01 | 0.231 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 5.931466e-01 | 0.227 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 5.961256e-01 | 0.225 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 5.961256e-01 | 0.225 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 5.961256e-01 | 0.225 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 5.961256e-01 | 0.225 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 5.961256e-01 | 0.225 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 5.961256e-01 | 0.225 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 5.961256e-01 | 0.225 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 5.961256e-01 | 0.225 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 5.970238e-01 | 0.224 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 5.970238e-01 | 0.224 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 5.970238e-01 | 0.224 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 5.994186e-01 | 0.222 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 6.074759e-01 | 0.216 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.107013e-01 | 0.214 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 6.107013e-01 | 0.214 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 6.107013e-01 | 0.214 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 6.149352e-01 | 0.211 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 6.161627e-01 | 0.210 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 6.161627e-01 | 0.210 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 6.216585e-01 | 0.206 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 6.227273e-01 | 0.206 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 6.233667e-01 | 0.205 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 6.280371e-01 | 0.202 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 6.334198e-01 | 0.198 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 6.334198e-01 | 0.198 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 6.334198e-01 | 0.198 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 6.334198e-01 | 0.198 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 6.334198e-01 | 0.198 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 6.334198e-01 | 0.198 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 6.334198e-01 | 0.198 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 6.334198e-01 | 0.198 | 0 | 0 |
| Trafficking of myristoylated proteins to the cilium | R-HSA-5624138 | 6.335687e-01 | 0.198 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 6.335687e-01 | 0.198 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 6.335687e-01 | 0.198 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 6.335687e-01 | 0.198 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 6.335687e-01 | 0.198 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 6.335687e-01 | 0.198 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 6.335687e-01 | 0.198 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 6.335687e-01 | 0.198 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 6.335687e-01 | 0.198 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 6.335687e-01 | 0.198 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 6.356840e-01 | 0.197 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 6.356840e-01 | 0.197 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 6.356840e-01 | 0.197 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 6.403495e-01 | 0.194 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 6.403495e-01 | 0.194 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 6.403495e-01 | 0.194 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 6.432954e-01 | 0.192 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 6.450710e-01 | 0.190 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 6.460322e-01 | 0.190 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 6.485913e-01 | 0.188 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 6.485913e-01 | 0.188 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 6.485913e-01 | 0.188 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 6.487797e-01 | 0.188 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 6.555720e-01 | 0.183 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 6.569581e-01 | 0.182 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 6.611616e-01 | 0.180 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 6.626130e-01 | 0.179 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 6.651150e-01 | 0.177 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 6.679621e-01 | 0.175 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 6.679621e-01 | 0.175 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 6.679621e-01 | 0.175 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 6.679621e-01 | 0.175 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 6.679621e-01 | 0.175 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 6.679621e-01 | 0.175 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 6.683716e-01 | 0.175 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 6.683716e-01 | 0.175 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 6.683716e-01 | 0.175 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 6.718562e-01 | 0.173 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 6.726671e-01 | 0.172 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 6.726671e-01 | 0.172 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 6.727647e-01 | 0.172 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 6.729625e-01 | 0.172 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 6.747490e-01 | 0.171 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 6.783074e-01 | 0.169 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 6.797150e-01 | 0.168 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 6.825391e-01 | 0.166 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 6.825391e-01 | 0.166 | 0 | 0 |
| Phase 1 - inactivation of fast Na+ channels | R-HSA-5576894 | 6.825391e-01 | 0.166 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 6.825391e-01 | 0.166 | 0 | 0 |
| Synthesis of dolichyl-phosphate mannose | R-HSA-162699 | 6.825391e-01 | 0.166 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 6.825391e-01 | 0.166 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 6.825391e-01 | 0.166 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 6.825391e-01 | 0.166 | 0 | 0 |
| Intestinal hexose absorption | R-HSA-8981373 | 6.825391e-01 | 0.166 | 0 | 0 |
| Relaxin receptors | R-HSA-444821 | 6.825391e-01 | 0.166 | 0 | 0 |
| Ligand-receptor interactions | R-HSA-5632681 | 6.825391e-01 | 0.166 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 6.876724e-01 | 0.163 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 6.880212e-01 | 0.162 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 6.906815e-01 | 0.161 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 6.906815e-01 | 0.161 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 6.919100e-01 | 0.160 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 6.942278e-01 | 0.158 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 6.945596e-01 | 0.158 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 6.947608e-01 | 0.158 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 6.947608e-01 | 0.158 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 6.947608e-01 | 0.158 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 6.947608e-01 | 0.158 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 6.947608e-01 | 0.158 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 6.950717e-01 | 0.158 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 6.955767e-01 | 0.158 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 6.969001e-01 | 0.157 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 6.987497e-01 | 0.156 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 6.987497e-01 | 0.156 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 6.987497e-01 | 0.156 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 6.998219e-01 | 0.155 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 6.998219e-01 | 0.155 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 6.998219e-01 | 0.155 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 6.998219e-01 | 0.155 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 6.998219e-01 | 0.155 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 6.998219e-01 | 0.155 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 6.998219e-01 | 0.155 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 7.009701e-01 | 0.154 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 7.009701e-01 | 0.154 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 7.074158e-01 | 0.150 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 7.074979e-01 | 0.150 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 7.077689e-01 | 0.150 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 7.173147e-01 | 0.144 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 7.173147e-01 | 0.144 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 7.173147e-01 | 0.144 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 7.182756e-01 | 0.144 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 7.195291e-01 | 0.143 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 7.195291e-01 | 0.143 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 7.214561e-01 | 0.142 | 0 | 0 |
| Chylomicron clearance | R-HSA-8964026 | 7.249674e-01 | 0.140 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 7.249674e-01 | 0.140 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 7.249674e-01 | 0.140 | 0 | 0 |
| Defective CHST3 causes SEDCJD | R-HSA-3595172 | 7.249674e-01 | 0.140 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 7.249674e-01 | 0.140 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 7.249674e-01 | 0.140 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 7.249674e-01 | 0.140 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 7.249674e-01 | 0.140 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 7.249674e-01 | 0.140 | 0 | 0 |
| Intracellular metabolism of fatty acids regulates insulin secretion | R-HSA-434313 | 7.249674e-01 | 0.140 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 7.249674e-01 | 0.140 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 7.249674e-01 | 0.140 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 7.249674e-01 | 0.140 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 7.249674e-01 | 0.140 | 0 | 0 |
| CREB3 factors activate genes | R-HSA-8874211 | 7.249674e-01 | 0.140 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 7.290991e-01 | 0.137 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 7.290991e-01 | 0.137 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 7.290991e-01 | 0.137 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 7.290991e-01 | 0.137 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 7.290991e-01 | 0.137 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 7.368827e-01 | 0.133 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 7.368827e-01 | 0.133 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 7.368827e-01 | 0.133 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 7.427044e-01 | 0.129 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 7.427044e-01 | 0.129 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 7.427044e-01 | 0.129 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 7.451132e-01 | 0.128 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 7.495518e-01 | 0.125 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 7.495518e-01 | 0.125 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 7.555762e-01 | 0.122 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 7.559149e-01 | 0.122 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 7.559149e-01 | 0.122 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 7.559149e-01 | 0.122 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 7.559149e-01 | 0.122 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 7.559149e-01 | 0.122 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 7.559149e-01 | 0.122 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 7.559149e-01 | 0.122 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 7.559149e-01 | 0.122 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 7.617274e-01 | 0.118 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 7.617274e-01 | 0.118 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 7.617274e-01 | 0.118 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 7.617274e-01 | 0.118 | 0 | 0 |
| Defective CHSY1 causes TPBS | R-HSA-3595177 | 7.617274e-01 | 0.118 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 7.617274e-01 | 0.118 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 7.617274e-01 | 0.118 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 7.617274e-01 | 0.118 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 7.617274e-01 | 0.118 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 7.617274e-01 | 0.118 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 7.617274e-01 | 0.118 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 7.617274e-01 | 0.118 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 7.643273e-01 | 0.117 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 7.643273e-01 | 0.117 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 7.643273e-01 | 0.117 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.696844e-01 | 0.114 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 7.696844e-01 | 0.114 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 7.697342e-01 | 0.114 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 7.697342e-01 | 0.114 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 7.701078e-01 | 0.113 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 7.706443e-01 | 0.113 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 7.712653e-01 | 0.113 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 7.715669e-01 | 0.113 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 7.722737e-01 | 0.112 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 7.748646e-01 | 0.111 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 7.767533e-01 | 0.110 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 7.804041e-01 | 0.108 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 7.804041e-01 | 0.108 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 7.804041e-01 | 0.108 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 7.804041e-01 | 0.108 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 7.804041e-01 | 0.108 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 7.804041e-01 | 0.108 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 7.821230e-01 | 0.107 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 7.835549e-01 | 0.106 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 7.837062e-01 | 0.106 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 7.837062e-01 | 0.106 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 7.844482e-01 | 0.105 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 7.844482e-01 | 0.105 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 7.844482e-01 | 0.105 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 7.844482e-01 | 0.105 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 7.845385e-01 | 0.105 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 7.845385e-01 | 0.105 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 7.852713e-01 | 0.105 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 7.860849e-01 | 0.105 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 7.872565e-01 | 0.104 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 7.921929e-01 | 0.101 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 7.935759e-01 | 0.100 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 7.935759e-01 | 0.100 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 7.935759e-01 | 0.100 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 7.935759e-01 | 0.100 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 7.935759e-01 | 0.100 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 7.935759e-01 | 0.100 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 7.935759e-01 | 0.100 | 0 | 0 |
| Nucleotide salvage defects | R-HSA-9734207 | 7.935759e-01 | 0.100 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 7.935759e-01 | 0.100 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 7.935759e-01 | 0.100 | 0 | 0 |
| Intestinal absorption | R-HSA-8963676 | 7.935759e-01 | 0.100 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 7.935759e-01 | 0.100 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 7.964857e-01 | 0.099 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 7.997794e-01 | 0.097 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 7.997794e-01 | 0.097 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 7.997794e-01 | 0.097 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 8.021947e-01 | 0.096 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 8.022780e-01 | 0.096 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 8.022780e-01 | 0.096 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 8.022780e-01 | 0.096 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 8.027096e-01 | 0.095 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 8.027096e-01 | 0.095 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 8.027096e-01 | 0.095 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 8.027096e-01 | 0.095 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 8.027096e-01 | 0.095 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 8.027096e-01 | 0.095 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 8.027096e-01 | 0.095 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 8.056595e-01 | 0.094 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 8.078531e-01 | 0.093 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 8.078531e-01 | 0.093 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 8.082022e-01 | 0.092 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 8.088718e-01 | 0.092 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 8.088718e-01 | 0.092 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 8.119571e-01 | 0.090 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 8.133953e-01 | 0.090 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 8.204219e-01 | 0.086 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.204219e-01 | 0.086 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 8.204219e-01 | 0.086 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 8.207158e-01 | 0.086 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 8.211691e-01 | 0.086 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 8.211691e-01 | 0.086 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 8.211691e-01 | 0.086 | 0 | 0 |
| Enzymatic degradation of Dopamine by monoamine oxidase | R-HSA-379398 | 8.211691e-01 | 0.086 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 8.211691e-01 | 0.086 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 8.211691e-01 | 0.086 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 8.211691e-01 | 0.086 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 8.211691e-01 | 0.086 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 8.211691e-01 | 0.086 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 8.211691e-01 | 0.086 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 8.211691e-01 | 0.086 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 8.229774e-01 | 0.085 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 8.229774e-01 | 0.085 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 8.229774e-01 | 0.085 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 8.229774e-01 | 0.085 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 8.229774e-01 | 0.085 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 8.239406e-01 | 0.084 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 8.239406e-01 | 0.084 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.279213e-01 | 0.082 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 8.290318e-01 | 0.081 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 8.291428e-01 | 0.081 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.297903e-01 | 0.081 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 8.328088e-01 | 0.079 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 8.364057e-01 | 0.078 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 8.364057e-01 | 0.078 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 8.377305e-01 | 0.077 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 8.380121e-01 | 0.077 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 8.380121e-01 | 0.077 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 8.381098e-01 | 0.077 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 8.408322e-01 | 0.075 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 8.413536e-01 | 0.075 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 8.413536e-01 | 0.075 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 8.413536e-01 | 0.075 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 8.436263e-01 | 0.074 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 8.436263e-01 | 0.074 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 8.450752e-01 | 0.073 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 8.450752e-01 | 0.073 | 0 | 0 |
| Enzymatic degradation of dopamine by COMT | R-HSA-379397 | 8.450752e-01 | 0.073 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 8.450752e-01 | 0.073 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 8.450752e-01 | 0.073 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 8.450752e-01 | 0.073 | 0 | 0 |
| Arachidonate production from DAG | R-HSA-426048 | 8.450752e-01 | 0.073 | 0 | 0 |
| Sperm Motility And Taxes | R-HSA-1300642 | 8.450752e-01 | 0.073 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 8.474592e-01 | 0.072 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 8.474592e-01 | 0.072 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 8.485624e-01 | 0.071 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 8.511464e-01 | 0.070 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 8.538753e-01 | 0.069 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 8.538753e-01 | 0.069 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 8.544708e-01 | 0.068 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 8.579818e-01 | 0.067 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 8.579818e-01 | 0.067 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 8.579818e-01 | 0.067 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 8.579818e-01 | 0.067 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 8.579818e-01 | 0.067 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 8.584995e-01 | 0.066 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 8.633320e-01 | 0.064 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 8.633320e-01 | 0.064 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 8.635726e-01 | 0.064 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 8.638090e-01 | 0.064 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.647148e-01 | 0.063 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 8.647148e-01 | 0.063 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 8.647148e-01 | 0.063 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 8.647148e-01 | 0.063 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 8.651310e-01 | 0.063 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 8.657867e-01 | 0.063 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 8.657867e-01 | 0.063 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 8.657867e-01 | 0.063 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 8.657867e-01 | 0.063 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 8.657867e-01 | 0.063 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 8.657867e-01 | 0.063 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 8.657867e-01 | 0.063 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 8.657867e-01 | 0.063 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 8.661932e-01 | 0.062 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 8.678968e-01 | 0.062 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 8.685249e-01 | 0.061 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 8.730007e-01 | 0.059 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 8.730007e-01 | 0.059 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 8.730007e-01 | 0.059 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 8.730007e-01 | 0.059 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 8.730007e-01 | 0.059 | 0 | 0 |
| Melanin biosynthesis | R-HSA-5662702 | 8.730007e-01 | 0.059 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 8.746684e-01 | 0.058 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 8.746684e-01 | 0.058 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 8.771817e-01 | 0.057 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 8.771817e-01 | 0.057 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 8.771817e-01 | 0.057 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 8.780151e-01 | 0.056 | 1 | 1 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 8.837304e-01 | 0.054 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 8.837304e-01 | 0.054 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 8.837304e-01 | 0.054 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 8.837304e-01 | 0.054 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 8.837304e-01 | 0.054 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 8.837304e-01 | 0.054 | 0 | 0 |
| FMO oxidises nucleophiles | R-HSA-217271 | 8.837304e-01 | 0.054 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 8.837304e-01 | 0.054 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 8.837304e-01 | 0.054 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 8.865434e-01 | 0.052 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 8.865434e-01 | 0.052 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 8.865434e-01 | 0.052 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 8.868033e-01 | 0.052 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 8.868033e-01 | 0.052 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 8.874137e-01 | 0.052 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 8.886173e-01 | 0.051 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 8.886173e-01 | 0.051 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.886173e-01 | 0.051 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 8.894925e-01 | 0.051 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 8.949181e-01 | 0.048 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.949181e-01 | 0.048 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 8.951046e-01 | 0.048 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 8.987361e-01 | 0.046 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 8.987361e-01 | 0.046 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 8.987361e-01 | 0.046 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 8.992760e-01 | 0.046 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.992760e-01 | 0.046 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.992760e-01 | 0.046 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.992760e-01 | 0.046 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 8.992760e-01 | 0.046 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 8.992760e-01 | 0.046 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.992760e-01 | 0.046 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.024570e-01 | 0.045 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.030776e-01 | 0.044 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.039206e-01 | 0.044 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.066709e-01 | 0.043 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.086666e-01 | 0.042 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.096976e-01 | 0.041 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 9.096976e-01 | 0.041 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 9.096976e-01 | 0.041 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 9.096976e-01 | 0.041 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 9.127439e-01 | 0.040 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 9.127439e-01 | 0.040 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 9.127439e-01 | 0.040 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 9.127439e-01 | 0.040 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 9.127439e-01 | 0.040 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.169508e-01 | 0.038 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.169508e-01 | 0.038 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 9.174110e-01 | 0.037 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 9.174110e-01 | 0.037 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 9.174110e-01 | 0.037 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 9.195390e-01 | 0.036 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.195390e-01 | 0.036 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 9.195390e-01 | 0.036 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.195390e-01 | 0.036 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.204793e-01 | 0.036 | 0 | 0 |
| Translation | R-HSA-72766 | 9.211895e-01 | 0.036 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 9.232947e-01 | 0.035 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 9.232947e-01 | 0.035 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 9.242154e-01 | 0.034 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 9.244117e-01 | 0.034 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 9.244117e-01 | 0.034 | 0 | 0 |
| Synthesis of IPs in the nucleus | R-HSA-1855191 | 9.244117e-01 | 0.034 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 9.244117e-01 | 0.034 | 0 | 0 |
| Glycerophospholipid catabolism | R-HSA-6814848 | 9.244117e-01 | 0.034 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 9.244117e-01 | 0.034 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 9.244117e-01 | 0.034 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 9.244117e-01 | 0.034 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 9.244117e-01 | 0.034 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 9.253849e-01 | 0.034 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.253849e-01 | 0.034 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.253849e-01 | 0.034 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 9.262084e-01 | 0.033 | 1 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.283640e-01 | 0.032 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 9.283640e-01 | 0.032 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 9.283640e-01 | 0.032 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.287489e-01 | 0.032 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 9.291260e-01 | 0.032 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 9.304464e-01 | 0.031 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.314943e-01 | 0.031 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 9.326467e-01 | 0.030 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 9.345198e-01 | 0.029 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 9.345198e-01 | 0.029 | 0 | 0 |
| Transport and metabolism of PAPS | R-HSA-174362 | 9.345198e-01 | 0.029 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 9.345198e-01 | 0.029 | 0 | 0 |
| Protein repair | R-HSA-5676934 | 9.345198e-01 | 0.029 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 9.345198e-01 | 0.029 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.347173e-01 | 0.029 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.362682e-01 | 0.029 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.362682e-01 | 0.029 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.392519e-01 | 0.027 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.392519e-01 | 0.027 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 9.394179e-01 | 0.027 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.432767e-01 | 0.025 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 9.432767e-01 | 0.025 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 9.432767e-01 | 0.025 | 0 | 0 |
| Serotonin and melatonin biosynthesis | R-HSA-209931 | 9.432767e-01 | 0.025 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.432767e-01 | 0.025 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 9.432767e-01 | 0.025 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.446045e-01 | 0.025 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 9.448926e-01 | 0.025 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 9.452527e-01 | 0.024 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 9.496609e-01 | 0.022 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 9.496609e-01 | 0.022 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.496609e-01 | 0.022 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.496609e-01 | 0.022 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.499114e-01 | 0.022 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.499114e-01 | 0.022 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.506985e-01 | 0.022 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 9.508630e-01 | 0.022 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 9.508630e-01 | 0.022 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 9.508630e-01 | 0.022 | 0 | 0 |
| Heme assimilation | R-HSA-9927020 | 9.508630e-01 | 0.022 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 9.508630e-01 | 0.022 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 9.508630e-01 | 0.022 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 9.528983e-01 | 0.021 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 9.549156e-01 | 0.020 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.549839e-01 | 0.020 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 9.553050e-01 | 0.020 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 9.553050e-01 | 0.020 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 9.553050e-01 | 0.020 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.553050e-01 | 0.020 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.556353e-01 | 0.020 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 9.574351e-01 | 0.019 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 9.574351e-01 | 0.019 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 9.574351e-01 | 0.019 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.574351e-01 | 0.019 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.579071e-01 | 0.019 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.587109e-01 | 0.018 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.601061e-01 | 0.018 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.603402e-01 | 0.018 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 9.603402e-01 | 0.018 | 1 | 1 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 9.613325e-01 | 0.017 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.615595e-01 | 0.017 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.623200e-01 | 0.017 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 9.631284e-01 | 0.016 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 9.631284e-01 | 0.016 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.631284e-01 | 0.016 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.631284e-01 | 0.016 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 9.631284e-01 | 0.016 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 9.641510e-01 | 0.016 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 9.641510e-01 | 0.016 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.648285e-01 | 0.016 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.652453e-01 | 0.015 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 9.676117e-01 | 0.014 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.678070e-01 | 0.014 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.678070e-01 | 0.014 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.680606e-01 | 0.014 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.680606e-01 | 0.014 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.680606e-01 | 0.014 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 9.680606e-01 | 0.014 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.680606e-01 | 0.014 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.688260e-01 | 0.014 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 9.688260e-01 | 0.014 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.711087e-01 | 0.013 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.719678e-01 | 0.012 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 9.721762e-01 | 0.012 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 9.723332e-01 | 0.012 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.723332e-01 | 0.012 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 9.723332e-01 | 0.012 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.723332e-01 | 0.012 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 9.723836e-01 | 0.012 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.730846e-01 | 0.012 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.735075e-01 | 0.012 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.737672e-01 | 0.012 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 9.740878e-01 | 0.011 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 9.740878e-01 | 0.011 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.748315e-01 | 0.011 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.749607e-01 | 0.011 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 9.751315e-01 | 0.011 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.755476e-01 | 0.011 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 9.755476e-01 | 0.011 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 9.760345e-01 | 0.011 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.760345e-01 | 0.011 | 0 | 0 |
| Synthesis of very long-chain fatty acyl-CoAs | R-HSA-75876 | 9.767736e-01 | 0.010 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 9.772473e-01 | 0.010 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.783595e-01 | 0.010 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 9.790422e-01 | 0.009 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.791931e-01 | 0.009 | 0 | 0 |
| CS-GAG biosynthesis | R-HSA-2022870 | 9.792408e-01 | 0.009 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 9.792408e-01 | 0.009 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.792408e-01 | 0.009 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.796830e-01 | 0.009 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.801563e-01 | 0.009 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 9.808570e-01 | 0.008 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.808570e-01 | 0.008 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 9.820183e-01 | 0.008 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 9.820183e-01 | 0.008 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.820183e-01 | 0.008 | 0 | 0 |
| Reactions specific to the complex N-glycan synthesis pathway | R-HSA-975578 | 9.820183e-01 | 0.008 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.820183e-01 | 0.008 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.820183e-01 | 0.008 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.820183e-01 | 0.008 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.820183e-01 | 0.008 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.830737e-01 | 0.007 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.832496e-01 | 0.007 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.833299e-01 | 0.007 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.844243e-01 | 0.007 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.844243e-01 | 0.007 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.844243e-01 | 0.007 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 9.844243e-01 | 0.007 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.848922e-01 | 0.007 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.850401e-01 | 0.007 | 0 | 0 |
| CYP2E1 reactions | R-HSA-211999 | 9.865085e-01 | 0.006 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 9.865085e-01 | 0.006 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 9.865085e-01 | 0.006 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.865085e-01 | 0.006 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.865085e-01 | 0.006 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.867834e-01 | 0.006 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.867834e-01 | 0.006 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 9.868248e-01 | 0.006 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.868248e-01 | 0.006 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.877297e-01 | 0.005 | 1 | 1 |
| Metabolism of cofactors | R-HSA-8978934 | 9.880560e-01 | 0.005 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.883139e-01 | 0.005 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.883139e-01 | 0.005 | 0 | 0 |
| Fertilization | R-HSA-1187000 | 9.883139e-01 | 0.005 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.883139e-01 | 0.005 | 0 | 0 |
| Retinoid cycle disease events | R-HSA-2453864 | 9.883139e-01 | 0.005 | 0 | 0 |
| Diseases of the neuronal system | R-HSA-9675143 | 9.883139e-01 | 0.005 | 0 | 0 |
| Diseases associated with visual transduction | R-HSA-2474795 | 9.883139e-01 | 0.005 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 9.883139e-01 | 0.005 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 9.883282e-01 | 0.005 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.883282e-01 | 0.005 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 9.888480e-01 | 0.005 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.889505e-01 | 0.005 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.893657e-01 | 0.005 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.896964e-01 | 0.004 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 9.898778e-01 | 0.004 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.898778e-01 | 0.004 | 0 | 0 |
| Linoleic acid (LA) metabolism | R-HSA-2046105 | 9.898778e-01 | 0.004 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.898778e-01 | 0.004 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.898778e-01 | 0.004 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 9.900427e-01 | 0.004 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 9.900547e-01 | 0.004 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.901990e-01 | 0.004 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.901990e-01 | 0.004 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.902297e-01 | 0.004 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.905075e-01 | 0.004 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.909075e-01 | 0.004 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 9.912325e-01 | 0.004 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 9.912325e-01 | 0.004 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.912325e-01 | 0.004 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 9.912325e-01 | 0.004 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.912477e-01 | 0.004 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.915306e-01 | 0.004 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.916210e-01 | 0.004 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.919732e-01 | 0.004 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.919790e-01 | 0.003 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 9.919790e-01 | 0.003 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.920795e-01 | 0.003 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.924467e-01 | 0.003 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.926833e-01 | 0.003 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 9.932666e-01 | 0.003 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 9.934224e-01 | 0.003 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.935041e-01 | 0.003 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.937645e-01 | 0.003 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.937645e-01 | 0.003 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.937645e-01 | 0.003 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.941669e-01 | 0.003 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 9.943029e-01 | 0.002 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.943614e-01 | 0.002 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 9.943719e-01 | 0.002 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.944944e-01 | 0.002 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.949976e-01 | 0.002 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.950655e-01 | 0.002 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.957261e-01 | 0.002 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 9.957261e-01 | 0.002 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.957360e-01 | 0.002 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.962235e-01 | 0.002 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.962235e-01 | 0.002 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.962235e-01 | 0.002 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.966490e-01 | 0.001 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.966490e-01 | 0.001 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.966519e-01 | 0.001 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.966519e-01 | 0.001 | 0 | 0 |
| CS/DS degradation | R-HSA-2024101 | 9.967939e-01 | 0.001 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.967939e-01 | 0.001 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.967946e-01 | 0.001 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.969790e-01 | 0.001 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.970814e-01 | 0.001 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.971289e-01 | 0.001 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.972232e-01 | 0.001 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.972232e-01 | 0.001 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.972232e-01 | 0.001 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 9.972232e-01 | 0.001 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.972857e-01 | 0.001 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 9.974301e-01 | 0.001 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 9.974301e-01 | 0.001 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.975950e-01 | 0.001 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.977495e-01 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.977495e-01 | 0.001 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.978528e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.979613e-01 | 0.001 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.979763e-01 | 0.001 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.980472e-01 | 0.001 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.981312e-01 | 0.001 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 9.981960e-01 | 0.001 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 9.981960e-01 | 0.001 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.981960e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.981960e-01 | 0.001 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.982615e-01 | 0.001 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.983418e-01 | 0.001 | 0 | 0 |
| Depurination | R-HSA-73927 | 9.984376e-01 | 0.001 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.984376e-01 | 0.001 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.984376e-01 | 0.001 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.984376e-01 | 0.001 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.985669e-01 | 0.001 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.986994e-01 | 0.001 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.987041e-01 | 0.001 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.988195e-01 | 0.001 | 0 | 0 |
| N-glycan antennae elongation in the medial/trans-Golgi | R-HSA-975576 | 9.988281e-01 | 0.001 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.989631e-01 | 0.000 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 9.989851e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.990786e-01 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.990878e-01 | 0.000 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.991211e-01 | 0.000 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 9.993408e-01 | 0.000 | 0 | 0 |
| Pyrimidine catabolism | R-HSA-73621 | 9.993408e-01 | 0.000 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.993840e-01 | 0.000 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.994291e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.994595e-01 | 0.000 | 0 | 0 |
| The canonical retinoid cycle in rods (twilight vision) | R-HSA-2453902 | 9.995056e-01 | 0.000 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.995056e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.995380e-01 | 0.000 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.996292e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.996292e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.996352e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.997527e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.997542e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.997542e-01 | 0.000 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.997915e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.998455e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.998551e-01 | 0.000 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.998731e-01 | 0.000 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 9.998828e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.999040e-01 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.999121e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999123e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.999459e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999500e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.999506e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999553e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.999617e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999617e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.999629e-01 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.999629e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999650e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.999679e-01 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.999753e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.999792e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999796e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999801e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.999820e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.999829e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.999865e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999878e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.999883e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.999890e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.999899e-01 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.999924e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999956e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.999957e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.999957e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999962e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.999963e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999964e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999966e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999974e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999978e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999979e-01 | 0.000 | 1 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999982e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.999983e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999983e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999987e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.999987e-01 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.999988e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999988e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999990e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.999991e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999995e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999997e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.999998e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999998e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999998e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999999e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999999e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999999e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 1 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 1 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.190499e-07 | 6.924 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 7.837288e-08 | 7.106 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 2.101123e-07 | 6.678 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 9.000355e-07 | 6.046 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.134062e-06 | 5.945 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.775891e-06 | 5.751 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.998481e-06 | 5.699 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 2.311061e-06 | 5.636 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 2.421880e-06 | 5.616 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 2.864921e-06 | 5.543 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 8.149404e-06 | 5.089 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.295551e-05 | 4.888 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.863955e-05 | 4.730 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.751804e-05 | 4.757 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 3.566814e-05 | 4.448 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 3.827585e-05 | 4.417 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 4.512812e-05 | 4.346 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 6.957364e-05 | 4.158 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 7.046358e-05 | 4.152 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 8.545601e-05 | 4.068 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 9.573587e-05 | 4.019 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.001557e-04 | 3.999 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 1.037083e-04 | 3.984 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.365286e-04 | 3.865 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 1.684531e-04 | 3.774 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 1.767663e-04 | 3.753 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.767663e-04 | 3.753 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 1.915434e-04 | 3.718 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.160622e-04 | 3.500 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 4.215787e-04 | 3.375 | 0 | 0 |
| Kinesins | R-HSA-983189 | 4.639824e-04 | 3.333 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 5.285081e-04 | 3.277 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 4.990350e-04 | 3.302 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 7.022437e-04 | 3.154 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 7.473777e-04 | 3.126 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 9.056225e-04 | 3.043 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 9.385691e-04 | 3.028 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.011241e-03 | 2.995 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.187091e-03 | 2.926 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.347330e-03 | 2.871 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.281569e-03 | 2.892 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 1.253702e-03 | 2.902 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.514719e-03 | 2.820 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.423113e-03 | 2.847 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.453870e-03 | 2.837 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.707415e-03 | 2.768 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.752663e-03 | 2.756 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.810865e-03 | 2.742 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 1.932434e-03 | 2.714 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 1.917983e-03 | 2.717 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.208534e-03 | 2.656 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.208534e-03 | 2.656 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 2.121734e-03 | 2.673 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 2.338942e-03 | 2.631 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 2.214737e-03 | 2.655 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 2.118362e-03 | 2.674 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.444221e-03 | 2.612 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 2.536562e-03 | 2.596 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.592392e-03 | 2.586 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 2.592392e-03 | 2.586 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.592392e-03 | 2.586 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 3.362107e-03 | 2.473 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 3.516153e-03 | 2.454 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 3.797803e-03 | 2.420 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 3.858908e-03 | 2.414 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 4.490051e-03 | 2.348 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 4.490051e-03 | 2.348 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 4.096300e-03 | 2.388 | 0 | 0 |
| M Phase | R-HSA-68886 | 4.515636e-03 | 2.345 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.490051e-03 | 2.348 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.490051e-03 | 2.348 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 4.227209e-03 | 2.374 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 4.521595e-03 | 2.345 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 4.746366e-03 | 2.324 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 4.813170e-03 | 2.318 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 5.187307e-03 | 2.285 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 5.424942e-03 | 2.266 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 5.578933e-03 | 2.253 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 5.613722e-03 | 2.251 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 6.641897e-03 | 2.178 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 6.224948e-03 | 2.206 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 6.641897e-03 | 2.178 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 5.693603e-03 | 2.245 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 6.759022e-03 | 2.170 | 1 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 6.763840e-03 | 2.170 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 6.791941e-03 | 2.168 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 6.867129e-03 | 2.163 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 6.905158e-03 | 2.161 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 7.012861e-03 | 2.154 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 7.087837e-03 | 2.149 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 7.656746e-03 | 2.116 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 7.704920e-03 | 2.113 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 8.321542e-03 | 2.080 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 8.720672e-03 | 2.059 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 8.765095e-03 | 2.057 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 1.035812e-02 | 1.985 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 1.235615e-02 | 1.908 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.091749e-02 | 1.962 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.258535e-02 | 1.900 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.282344e-02 | 1.892 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 1.343108e-02 | 1.872 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.357526e-02 | 1.867 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.368478e-02 | 1.864 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.393760e-02 | 1.856 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 1.417106e-02 | 1.849 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.537882e-02 | 1.813 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.537882e-02 | 1.813 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.547087e-02 | 1.810 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.629286e-02 | 1.788 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.633787e-02 | 1.787 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.833681e-02 | 1.737 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.833681e-02 | 1.737 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.833681e-02 | 1.737 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.833681e-02 | 1.737 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.833681e-02 | 1.737 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 1.924286e-02 | 1.716 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.957831e-02 | 1.708 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 2.060202e-02 | 1.686 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 2.025313e-02 | 1.694 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.887631e-02 | 1.724 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.211208e-02 | 1.655 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 2.285629e-02 | 1.641 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 2.297748e-02 | 1.639 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 2.297748e-02 | 1.639 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 2.351452e-02 | 1.629 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.634312e-02 | 1.579 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 2.779442e-02 | 1.556 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 2.816214e-02 | 1.550 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 2.816214e-02 | 1.550 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 2.816214e-02 | 1.550 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 3.194611e-02 | 1.496 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 3.506875e-02 | 1.455 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 3.633961e-02 | 1.440 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 3.797141e-02 | 1.421 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 3.797141e-02 | 1.421 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 4.006900e-02 | 1.397 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 4.006900e-02 | 1.397 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 4.887928e-02 | 1.311 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 4.220953e-02 | 1.375 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 4.883847e-02 | 1.311 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 4.220953e-02 | 1.375 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 3.922843e-02 | 1.406 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.965755e-02 | 1.402 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 4.050049e-02 | 1.393 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 3.731164e-02 | 1.428 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 4.439205e-02 | 1.353 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 4.661561e-02 | 1.331 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 4.219263e-02 | 1.375 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.901676e-02 | 1.310 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 5.118216e-02 | 1.291 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 5.352332e-02 | 1.271 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 5.401442e-02 | 1.267 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 5.401442e-02 | 1.267 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 5.676959e-02 | 1.246 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 5.831699e-02 | 1.234 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 5.831699e-02 | 1.234 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 5.850178e-02 | 1.233 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 6.076775e-02 | 1.216 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 6.273069e-02 | 1.203 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 6.325332e-02 | 1.199 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 6.546355e-02 | 1.184 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 6.832554e-02 | 1.165 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 7.006075e-02 | 1.155 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 7.045174e-02 | 1.152 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 7.091056e-02 | 1.149 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 7.091056e-02 | 1.149 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 7.091056e-02 | 1.149 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 7.091056e-02 | 1.149 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 7.091056e-02 | 1.149 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 7.091056e-02 | 1.149 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 7.136719e-02 | 1.147 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 7.136719e-02 | 1.147 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 7.136719e-02 | 1.147 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 7.166213e-02 | 1.145 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 7.352710e-02 | 1.134 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 7.992463e-02 | 1.097 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.071083e-01 | 0.970 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.100668e-01 | 0.958 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 1.100668e-01 | 0.958 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 8.840374e-02 | 1.054 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 7.617438e-02 | 1.118 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 7.617438e-02 | 1.118 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 8.984494e-02 | 1.047 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 8.984494e-02 | 1.047 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 8.984494e-02 | 1.047 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.051298e-01 | 0.978 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.051298e-01 | 0.978 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 8.984494e-02 | 1.047 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 9.550193e-02 | 1.020 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 8.407174e-02 | 1.075 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 8.822614e-02 | 1.054 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.142460e-01 | 0.942 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 8.125809e-02 | 1.090 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.361217e-02 | 1.029 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 8.794044e-02 | 1.056 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 8.429289e-02 | 1.074 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 1.002230e-01 | 0.999 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.160477e-01 | 0.935 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 1.160477e-01 | 0.935 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.183345e-01 | 0.927 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.184310e-01 | 0.927 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.190687e-01 | 0.924 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 1.215510e-01 | 0.915 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 1.282469e-01 | 0.892 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.282469e-01 | 0.892 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.376728e-01 | 0.861 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.456232e-01 | 0.837 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.690401e-01 | 0.772 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 1.690401e-01 | 0.772 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 1.690401e-01 | 0.772 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.690401e-01 | 0.772 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.842960e-01 | 0.734 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 1.842960e-01 | 0.734 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 1.992737e-01 | 0.701 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 1.992737e-01 | 0.701 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 2.139782e-01 | 0.670 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 2.212295e-01 | 0.655 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 2.355334e-01 | 0.628 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 2.355334e-01 | 0.628 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 2.355334e-01 | 0.628 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 1.599111e-01 | 0.796 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 1.566805e-01 | 0.805 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 1.470679e-01 | 0.832 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 1.456232e-01 | 0.837 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 2.066598e-01 | 0.685 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.762395e-01 | 0.754 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 1.842960e-01 | 0.734 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 1.613062e-01 | 0.792 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 1.856157e-01 | 0.731 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.565015e-01 | 0.591 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.664088e-01 | 0.779 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.879321e-01 | 0.726 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 1.535008e-01 | 0.814 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 1.828437e-01 | 0.738 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 2.095876e-01 | 0.679 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.129604e-01 | 0.672 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.296490e-01 | 0.887 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 1.918193e-01 | 0.717 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 1.992737e-01 | 0.701 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.344556e-01 | 0.871 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.918193e-01 | 0.717 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.664088e-01 | 0.779 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.066598e-01 | 0.685 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 2.210868e-01 | 0.655 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.696750e-01 | 0.770 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 1.961571e-01 | 0.707 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 2.469197e-01 | 0.607 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 1.729520e-01 | 0.762 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.613062e-01 | 0.792 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 1.376728e-01 | 0.861 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 1.613062e-01 | 0.792 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 1.613062e-01 | 0.792 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 1.690401e-01 | 0.772 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.425872e-01 | 0.615 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.495764e-01 | 0.603 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.534628e-01 | 0.814 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.565015e-01 | 0.591 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.313426e-01 | 0.882 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.894841e-01 | 0.722 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 2.114870e-01 | 0.675 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.613062e-01 | 0.792 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.565015e-01 | 0.591 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 2.066598e-01 | 0.685 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.306309e-01 | 0.884 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 2.139782e-01 | 0.670 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 2.139782e-01 | 0.670 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.535008e-01 | 0.814 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 2.284144e-01 | 0.641 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 2.495764e-01 | 0.603 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 2.565015e-01 | 0.591 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 2.139782e-01 | 0.670 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 2.495764e-01 | 0.603 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.285673e-01 | 0.891 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.767031e-01 | 0.753 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 2.511341e-01 | 0.600 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.762395e-01 | 0.754 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.613062e-01 | 0.792 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.495764e-01 | 0.603 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.495764e-01 | 0.603 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 1.450477e-01 | 0.838 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 2.565015e-01 | 0.591 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 1.918193e-01 | 0.717 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 1.918193e-01 | 0.717 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 2.565015e-01 | 0.591 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.696262e-01 | 0.771 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.131640e-01 | 0.671 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.664088e-01 | 0.779 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.645477e-01 | 0.784 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 2.495764e-01 | 0.603 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 2.131397e-01 | 0.671 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.984618e-01 | 0.702 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 1.894841e-01 | 0.722 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.284144e-01 | 0.641 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 2.347273e-01 | 0.629 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.411218e-01 | 0.850 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 2.495764e-01 | 0.603 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.391557e-01 | 0.621 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 1.856157e-01 | 0.731 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.842960e-01 | 0.734 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.842960e-01 | 0.734 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 1.456232e-01 | 0.837 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.708554e-01 | 0.767 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 2.425872e-01 | 0.615 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 1.718852e-01 | 0.765 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 2.633631e-01 | 0.579 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.633631e-01 | 0.579 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 2.639876e-01 | 0.578 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 2.674031e-01 | 0.573 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 2.701618e-01 | 0.568 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 2.701618e-01 | 0.568 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.701618e-01 | 0.568 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 2.701618e-01 | 0.568 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 2.764912e-01 | 0.558 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 2.768981e-01 | 0.558 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 2.768981e-01 | 0.558 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 2.824619e-01 | 0.549 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 2.835727e-01 | 0.547 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 2.835727e-01 | 0.547 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 2.835727e-01 | 0.547 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 2.835727e-01 | 0.547 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 2.878849e-01 | 0.541 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.878849e-01 | 0.541 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 2.901861e-01 | 0.537 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 2.901861e-01 | 0.537 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 2.901861e-01 | 0.537 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 2.912942e-01 | 0.536 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 2.912942e-01 | 0.536 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 2.947015e-01 | 0.531 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 2.967389e-01 | 0.528 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.981065e-01 | 0.526 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 3.000122e-01 | 0.523 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 3.015092e-01 | 0.521 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 3.015092e-01 | 0.521 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 3.032315e-01 | 0.518 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 3.032315e-01 | 0.518 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 3.032315e-01 | 0.518 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 3.032315e-01 | 0.518 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.032315e-01 | 0.518 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 3.032315e-01 | 0.518 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 3.032315e-01 | 0.518 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 3.032315e-01 | 0.518 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 3.083061e-01 | 0.511 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 3.096647e-01 | 0.509 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 3.096647e-01 | 0.509 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.096647e-01 | 0.509 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 3.096647e-01 | 0.509 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 3.096647e-01 | 0.509 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 3.116999e-01 | 0.506 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.146969e-01 | 0.502 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 3.160388e-01 | 0.500 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 3.160388e-01 | 0.500 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 3.160388e-01 | 0.500 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.160388e-01 | 0.500 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 3.160388e-01 | 0.500 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 3.223545e-01 | 0.492 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 3.223545e-01 | 0.492 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 3.252390e-01 | 0.488 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 3.286122e-01 | 0.483 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 3.286122e-01 | 0.483 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 3.286122e-01 | 0.483 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 3.286122e-01 | 0.483 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 3.286122e-01 | 0.483 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.286122e-01 | 0.483 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 3.286122e-01 | 0.483 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.286122e-01 | 0.483 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 3.286136e-01 | 0.483 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 3.348125e-01 | 0.475 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 3.353493e-01 | 0.475 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 3.409560e-01 | 0.467 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 3.470430e-01 | 0.460 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 3.470430e-01 | 0.460 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 3.470430e-01 | 0.460 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 3.470430e-01 | 0.460 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 3.470430e-01 | 0.460 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 3.487605e-01 | 0.457 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 3.487605e-01 | 0.457 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 3.530743e-01 | 0.452 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 3.530743e-01 | 0.452 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 3.530743e-01 | 0.452 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 3.530743e-01 | 0.452 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 3.530743e-01 | 0.452 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.530743e-01 | 0.452 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 3.554330e-01 | 0.449 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 3.587604e-01 | 0.445 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 3.587604e-01 | 0.445 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 3.590502e-01 | 0.445 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 3.590502e-01 | 0.445 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 3.590502e-01 | 0.445 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 3.590502e-01 | 0.445 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 3.590502e-01 | 0.445 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 3.649712e-01 | 0.438 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 3.649712e-01 | 0.438 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 3.649712e-01 | 0.438 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 3.649712e-01 | 0.438 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 3.708380e-01 | 0.431 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 3.708380e-01 | 0.431 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.708380e-01 | 0.431 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 3.766509e-01 | 0.424 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 3.766509e-01 | 0.424 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 3.766509e-01 | 0.424 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 3.766509e-01 | 0.424 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 3.785895e-01 | 0.422 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 3.785895e-01 | 0.422 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 3.823523e-01 | 0.418 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 3.824104e-01 | 0.417 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 3.824104e-01 | 0.417 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 3.824104e-01 | 0.417 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 3.824104e-01 | 0.417 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 3.881171e-01 | 0.411 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 3.881171e-01 | 0.411 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 3.881171e-01 | 0.411 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 3.881171e-01 | 0.411 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 3.881171e-01 | 0.411 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 3.881171e-01 | 0.411 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 3.937714e-01 | 0.405 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 3.937714e-01 | 0.405 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.937714e-01 | 0.405 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 3.937714e-01 | 0.405 | 1 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 3.937714e-01 | 0.405 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 3.993738e-01 | 0.399 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 4.006894e-01 | 0.397 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 4.013978e-01 | 0.396 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 4.049247e-01 | 0.393 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 4.158743e-01 | 0.381 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 4.179709e-01 | 0.379 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 4.212737e-01 | 0.375 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.238105e-01 | 0.373 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 4.253295e-01 | 0.371 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 4.266236e-01 | 0.370 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 4.266236e-01 | 0.370 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 4.266236e-01 | 0.370 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 4.319244e-01 | 0.365 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 4.319244e-01 | 0.365 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 4.371765e-01 | 0.359 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 4.371765e-01 | 0.359 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 4.423803e-01 | 0.354 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 4.458187e-01 | 0.351 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 4.475364e-01 | 0.349 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 4.475364e-01 | 0.349 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.475364e-01 | 0.349 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 4.526451e-01 | 0.344 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.526451e-01 | 0.344 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 4.550641e-01 | 0.342 | 0 | 0 |
| S Phase | R-HSA-69242 | 4.550641e-01 | 0.342 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.577069e-01 | 0.339 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 4.577069e-01 | 0.339 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 4.577069e-01 | 0.339 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 4.627221e-01 | 0.335 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 4.627221e-01 | 0.335 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 4.627221e-01 | 0.335 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 4.642521e-01 | 0.333 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 4.672948e-01 | 0.330 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 4.676913e-01 | 0.330 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 4.703272e-01 | 0.328 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 4.733495e-01 | 0.325 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 4.763614e-01 | 0.322 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 4.774932e-01 | 0.321 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 4.774932e-01 | 0.321 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 4.774932e-01 | 0.321 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 4.774932e-01 | 0.321 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 4.823267e-01 | 0.317 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 4.912644e-01 | 0.309 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 4.912644e-01 | 0.309 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 4.965623e-01 | 0.304 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 5.012205e-01 | 0.300 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 5.058359e-01 | 0.296 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 5.058359e-01 | 0.296 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 5.129678e-01 | 0.290 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.149399e-01 | 0.288 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 5.149399e-01 | 0.288 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 5.157315e-01 | 0.288 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.194292e-01 | 0.284 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.194292e-01 | 0.284 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 5.194292e-01 | 0.284 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 5.194292e-01 | 0.284 | 0 | 0 |
| Immune System | R-HSA-168256 | 5.202087e-01 | 0.284 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 5.238773e-01 | 0.281 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 5.238773e-01 | 0.281 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 5.238773e-01 | 0.281 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 5.259312e-01 | 0.279 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 5.282844e-01 | 0.277 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 5.310031e-01 | 0.275 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 5.315539e-01 | 0.274 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 5.326510e-01 | 0.274 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.326510e-01 | 0.274 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 5.369775e-01 | 0.270 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 5.369775e-01 | 0.270 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 5.371314e-01 | 0.270 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 5.412642e-01 | 0.267 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 5.455114e-01 | 0.263 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 5.481500e-01 | 0.261 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 5.497196e-01 | 0.260 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 5.538891e-01 | 0.257 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 5.552620e-01 | 0.256 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 5.580203e-01 | 0.253 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 5.621134e-01 | 0.250 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 5.621134e-01 | 0.250 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 5.661689e-01 | 0.247 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 5.661689e-01 | 0.247 | 0 | 0 |
| Disease | R-HSA-1643685 | 5.683735e-01 | 0.245 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 5.701871e-01 | 0.244 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 5.741683e-01 | 0.241 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 5.791166e-01 | 0.237 | 1 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 5.801017e-01 | 0.236 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 5.820211e-01 | 0.235 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 5.826890e-01 | 0.235 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 5.858934e-01 | 0.232 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 5.858934e-01 | 0.232 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 5.897301e-01 | 0.229 | 1 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 5.972979e-01 | 0.224 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 6.010296e-01 | 0.221 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 6.010296e-01 | 0.221 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 6.103797e-01 | 0.214 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 6.191791e-01 | 0.208 | 1 | 1 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 6.227094e-01 | 0.206 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 6.227094e-01 | 0.206 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 6.296727e-01 | 0.201 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 6.331063e-01 | 0.199 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 6.331063e-01 | 0.199 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 6.365083e-01 | 0.196 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 6.365083e-01 | 0.196 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 6.365083e-01 | 0.196 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 6.398790e-01 | 0.194 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 6.432186e-01 | 0.192 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 6.432186e-01 | 0.192 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 6.465274e-01 | 0.189 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 6.498058e-01 | 0.187 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 6.498058e-01 | 0.187 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 6.530540e-01 | 0.185 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 6.594608e-01 | 0.181 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 6.610617e-01 | 0.180 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 6.626200e-01 | 0.179 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 6.719240e-01 | 0.173 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 6.719240e-01 | 0.173 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.719240e-01 | 0.173 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.719240e-01 | 0.173 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 6.719240e-01 | 0.173 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.749683e-01 | 0.171 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 6.779846e-01 | 0.169 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 6.779846e-01 | 0.169 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 6.839340e-01 | 0.165 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 6.839340e-01 | 0.165 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 6.868676e-01 | 0.163 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.897742e-01 | 0.161 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 6.905625e-01 | 0.161 | 1 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 6.952921e-01 | 0.158 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 6.955072e-01 | 0.158 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 6.983341e-01 | 0.156 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 7.011350e-01 | 0.154 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 7.011350e-01 | 0.154 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 7.039100e-01 | 0.152 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 7.039100e-01 | 0.152 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 7.057958e-01 | 0.151 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 7.066594e-01 | 0.151 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 7.093834e-01 | 0.149 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 7.126073e-01 | 0.147 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 7.147564e-01 | 0.146 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 7.226314e-01 | 0.141 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 7.277610e-01 | 0.138 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 7.299085e-01 | 0.137 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 7.352792e-01 | 0.134 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 7.353346e-01 | 0.134 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 7.473541e-01 | 0.126 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 7.476713e-01 | 0.126 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 7.611237e-01 | 0.119 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 7.633450e-01 | 0.117 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 7.783302e-01 | 0.109 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 7.817481e-01 | 0.107 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 7.824358e-01 | 0.107 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 7.864659e-01 | 0.104 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 7.907198e-01 | 0.102 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 7.921833e-01 | 0.101 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 7.943050e-01 | 0.100 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 7.943050e-01 | 0.100 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 7.962197e-01 | 0.099 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 7.981167e-01 | 0.098 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 8.037030e-01 | 0.095 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.055308e-01 | 0.094 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 8.128620e-01 | 0.090 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.212383e-01 | 0.086 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 8.278086e-01 | 0.082 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.278086e-01 | 0.082 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 8.310032e-01 | 0.080 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 8.380405e-01 | 0.077 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 8.402380e-01 | 0.076 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 8.489713e-01 | 0.071 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 8.493626e-01 | 0.071 | 1 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 8.504546e-01 | 0.070 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 8.517758e-01 | 0.070 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 8.522250e-01 | 0.069 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 8.545284e-01 | 0.068 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 8.558080e-01 | 0.068 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.558857e-01 | 0.068 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 8.700101e-01 | 0.060 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 8.712238e-01 | 0.060 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 8.736175e-01 | 0.059 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 8.849392e-01 | 0.053 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 8.912425e-01 | 0.050 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.019208e-01 | 0.045 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.028382e-01 | 0.044 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.046477e-01 | 0.044 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.081668e-01 | 0.042 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 9.084449e-01 | 0.042 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.171931e-01 | 0.038 | 0 | 0 |
| Translation | R-HSA-72766 | 9.225803e-01 | 0.035 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 9.239184e-01 | 0.034 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.473221e-01 | 0.024 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.725716e-01 | 0.012 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.795611e-01 | 0.009 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.801353e-01 | 0.009 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.819360e-01 | 0.008 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.850653e-01 | 0.007 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.885619e-01 | 0.005 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.958623e-01 | 0.002 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.968298e-01 | 0.001 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.994707e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.997645e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.999423e-01 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.999946e-01 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | 0.000 | 1 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 1.000000e+00 | 0.000 | 1 | 1 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 1.000000e+00 | 0.000 | 1 | 1 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cellular response to heat stress | R-HSA-3371556 | 1.507905e-11 | 10.822 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 3.041845e-11 | 10.517 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 9.425150e-11 | 10.026 | 1 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 3.950207e-09 | 8.403 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 5.286035e-09 | 8.277 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 6.093163e-09 | 8.215 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 8.310489e-09 | 8.080 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.025848e-08 | 7.989 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.632436e-08 | 7.580 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 3.938585e-08 | 7.405 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.852383e-07 | 6.732 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.947260e-07 | 6.531 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 3.460973e-07 | 6.461 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 5.811743e-07 | 6.236 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 9.209573e-07 | 6.036 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.556480e-06 | 5.808 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.551711e-06 | 5.809 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.450360e-06 | 5.839 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.992011e-06 | 5.701 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.134165e-06 | 5.671 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.134165e-06 | 5.671 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.354786e-06 | 5.628 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 2.473032e-06 | 5.607 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 3.040774e-06 | 5.517 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 3.555584e-06 | 5.449 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 4.282988e-06 | 5.368 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 4.282988e-06 | 5.368 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 5.137810e-06 | 5.289 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 5.471680e-06 | 5.262 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 5.955444e-06 | 5.225 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 6.422195e-06 | 5.192 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 6.576583e-06 | 5.182 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 7.364107e-06 | 5.133 | 0 | 0 |
| M Phase | R-HSA-68886 | 7.824618e-06 | 5.107 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 7.763439e-06 | 5.110 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.095908e-05 | 4.960 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.167823e-05 | 4.933 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.367278e-05 | 4.864 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 1.369417e-05 | 4.863 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.991801e-05 | 4.701 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 2.145113e-05 | 4.669 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 2.411578e-05 | 4.618 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 2.678975e-05 | 4.572 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 3.117996e-05 | 4.506 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 3.064466e-05 | 4.514 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 3.123390e-05 | 4.505 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 3.492642e-05 | 4.457 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 4.399406e-05 | 4.357 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 5.937214e-05 | 4.226 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 6.866775e-05 | 4.163 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 7.459324e-05 | 4.127 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 8.132654e-05 | 4.090 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 8.318940e-05 | 4.080 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 8.581915e-05 | 4.066 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 9.799596e-05 | 4.009 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.036048e-04 | 3.985 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.094055e-04 | 3.961 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.375616e-04 | 3.862 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.612658e-04 | 3.792 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.668865e-04 | 3.778 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 2.024650e-04 | 3.694 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 2.370145e-04 | 3.625 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.601875e-04 | 3.585 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.964363e-04 | 3.528 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.987386e-04 | 3.525 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.987386e-04 | 3.525 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.987386e-04 | 3.525 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 2.844289e-04 | 3.546 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.987386e-04 | 3.525 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 3.189409e-04 | 3.496 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 3.395916e-04 | 3.469 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 3.499229e-04 | 3.456 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 3.904612e-04 | 3.408 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 4.054465e-04 | 3.392 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.394917e-04 | 3.357 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 4.610788e-04 | 3.336 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 4.827779e-04 | 3.316 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 5.099535e-04 | 3.292 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 5.110467e-04 | 3.292 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 5.222828e-04 | 3.282 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 5.355697e-04 | 3.271 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 5.689745e-04 | 3.245 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 5.809304e-04 | 3.236 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 5.952716e-04 | 3.225 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 6.282960e-04 | 3.202 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 7.104050e-04 | 3.148 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 7.104050e-04 | 3.148 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 6.932845e-04 | 3.159 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 6.817513e-04 | 3.166 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 7.596527e-04 | 3.119 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 8.560139e-04 | 3.068 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 9.476314e-04 | 3.023 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 9.476314e-04 | 3.023 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 9.226585e-04 | 3.035 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 9.672672e-04 | 3.014 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 1.030189e-03 | 2.987 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.101183e-03 | 2.958 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.113234e-03 | 2.953 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.161439e-03 | 2.935 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 1.230699e-03 | 2.910 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.230699e-03 | 2.910 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 1.270684e-03 | 2.896 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 1.305336e-03 | 2.884 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.322086e-03 | 2.879 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 1.322086e-03 | 2.879 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.420120e-03 | 2.848 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.403236e-03 | 2.853 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.440274e-03 | 2.842 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.505537e-03 | 2.822 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.547402e-03 | 2.810 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.547402e-03 | 2.810 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.447062e-03 | 2.840 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.533731e-03 | 2.814 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.488937e-03 | 2.827 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 1.540310e-03 | 2.812 | 0 | 0 |
| RSK activation | R-HSA-444257 | 1.607539e-03 | 2.794 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.607539e-03 | 2.794 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.743208e-03 | 2.759 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.870139e-03 | 2.728 | 1 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.939557e-03 | 2.712 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.026368e-03 | 2.693 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 2.123549e-03 | 2.673 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 2.237162e-03 | 2.650 | 0 | 0 |
| Protein folding | R-HSA-391251 | 2.277673e-03 | 2.643 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.425266e-03 | 2.615 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.516493e-03 | 2.599 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 2.601320e-03 | 2.585 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 2.601320e-03 | 2.585 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 2.604665e-03 | 2.584 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 2.613695e-03 | 2.583 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 2.613695e-03 | 2.583 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 2.768062e-03 | 2.558 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 2.956109e-03 | 2.529 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.956109e-03 | 2.529 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.794091e-03 | 2.554 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 2.942468e-03 | 2.531 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 3.085262e-03 | 2.511 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 3.389334e-03 | 2.470 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 3.389334e-03 | 2.470 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 3.389334e-03 | 2.470 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 3.389334e-03 | 2.470 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 3.389334e-03 | 2.470 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 3.389334e-03 | 2.470 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 3.389334e-03 | 2.470 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 3.389334e-03 | 2.470 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 3.389334e-03 | 2.470 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 3.389334e-03 | 2.470 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 3.389334e-03 | 2.470 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 3.381909e-03 | 2.471 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 3.161632e-03 | 2.500 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 3.161632e-03 | 2.500 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.443965e-03 | 2.463 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 3.695414e-03 | 2.432 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 3.695414e-03 | 2.432 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 3.735917e-03 | 2.428 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 3.890129e-03 | 2.410 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 4.010460e-03 | 2.397 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 4.132623e-03 | 2.384 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 4.544746e-03 | 2.342 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 4.856856e-03 | 2.314 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 4.856856e-03 | 2.314 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 4.837980e-03 | 2.315 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 4.822106e-03 | 2.317 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 5.116124e-03 | 2.291 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 5.116124e-03 | 2.291 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 5.116124e-03 | 2.291 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 5.248092e-03 | 2.280 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 5.316450e-03 | 2.274 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 5.316450e-03 | 2.274 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 5.380264e-03 | 2.269 | 0 | 0 |
| S Phase | R-HSA-69242 | 5.387822e-03 | 2.269 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 5.387822e-03 | 2.269 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 5.396587e-03 | 2.268 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 5.565351e-03 | 2.255 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 5.873476e-03 | 2.231 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 5.967931e-03 | 2.224 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 6.025489e-03 | 2.220 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 6.079928e-03 | 2.216 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 6.705801e-03 | 2.174 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 6.705801e-03 | 2.174 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 6.599622e-03 | 2.180 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 6.149454e-03 | 2.211 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 6.799134e-03 | 2.168 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 6.264104e-03 | 2.203 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 6.482979e-03 | 2.188 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 7.003711e-03 | 2.155 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 7.049080e-03 | 2.152 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 7.049080e-03 | 2.152 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 7.277941e-03 | 2.138 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 7.358632e-03 | 2.133 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 7.365678e-03 | 2.133 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 7.512701e-03 | 2.124 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 7.825596e-03 | 2.106 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 7.904646e-03 | 2.102 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 7.904646e-03 | 2.102 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 7.904646e-03 | 2.102 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 7.992019e-03 | 2.097 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 8.009926e-03 | 2.096 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 8.156326e-03 | 2.089 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 8.935201e-03 | 2.049 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 8.799911e-03 | 2.056 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 9.176852e-03 | 2.037 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 8.499095e-03 | 2.071 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 9.176852e-03 | 2.037 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 8.906540e-03 | 2.050 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 9.089531e-03 | 2.041 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 8.955597e-03 | 2.048 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 8.799911e-03 | 2.056 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 9.373172e-03 | 2.028 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 9.419792e-03 | 2.026 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 9.990114e-03 | 2.000 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 1.018877e-02 | 1.992 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.031047e-02 | 1.987 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.041234e-02 | 1.982 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.041234e-02 | 1.982 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 1.041234e-02 | 1.982 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 1.043395e-02 | 1.982 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.080264e-02 | 1.966 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 1.080264e-02 | 1.966 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.094511e-02 | 1.961 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.127833e-02 | 1.948 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.144889e-02 | 1.941 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 1.168322e-02 | 1.932 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 1.173228e-02 | 1.931 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.173228e-02 | 1.931 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.176960e-02 | 1.929 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.357871e-02 | 1.867 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 1.357871e-02 | 1.867 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 1.249543e-02 | 1.903 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 1.303630e-02 | 1.885 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.332042e-02 | 1.875 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.293274e-02 | 1.888 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.271247e-02 | 1.896 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.293274e-02 | 1.888 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 1.321473e-02 | 1.879 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.373511e-02 | 1.862 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.332042e-02 | 1.875 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.373511e-02 | 1.862 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.373511e-02 | 1.862 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 1.488661e-02 | 1.827 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.495288e-02 | 1.825 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.498931e-02 | 1.824 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.498931e-02 | 1.824 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.500447e-02 | 1.824 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 1.500447e-02 | 1.824 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 1.536650e-02 | 1.813 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 1.536650e-02 | 1.813 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 1.536650e-02 | 1.813 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 1.537221e-02 | 1.813 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 1.537221e-02 | 1.813 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 1.537221e-02 | 1.813 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 1.537221e-02 | 1.813 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.581247e-02 | 1.801 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 1.581247e-02 | 1.801 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 1.581765e-02 | 1.801 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 1.581765e-02 | 1.801 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.581765e-02 | 1.801 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.876072e-02 | 1.727 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 1.876072e-02 | 1.727 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.732273e-02 | 1.761 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.727275e-02 | 1.763 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.690625e-02 | 1.772 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.613491e-02 | 1.792 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.613491e-02 | 1.792 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.715903e-02 | 1.766 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.867925e-02 | 1.729 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.774788e-02 | 1.751 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.665332e-02 | 1.778 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.715903e-02 | 1.766 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.727275e-02 | 1.763 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 1.639829e-02 | 1.785 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.867925e-02 | 1.729 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 1.715903e-02 | 1.766 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.908351e-02 | 1.719 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.929523e-02 | 1.715 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.939815e-02 | 1.712 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.947669e-02 | 1.710 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.002115e-02 | 1.699 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.002115e-02 | 1.699 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 2.037627e-02 | 1.691 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 2.067099e-02 | 1.685 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 2.073894e-02 | 1.683 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.075901e-02 | 1.683 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 2.080901e-02 | 1.682 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 2.115462e-02 | 1.675 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 2.128476e-02 | 1.672 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 2.160670e-02 | 1.665 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.160670e-02 | 1.665 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 2.222556e-02 | 1.653 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 2.240183e-02 | 1.650 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.240183e-02 | 1.650 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 2.282346e-02 | 1.642 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 2.328373e-02 | 1.633 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 2.328373e-02 | 1.633 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 2.328373e-02 | 1.633 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 2.680214e-02 | 1.572 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 2.680214e-02 | 1.572 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 2.680904e-02 | 1.572 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 2.680904e-02 | 1.572 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 2.516299e-02 | 1.599 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 2.516299e-02 | 1.599 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.516299e-02 | 1.599 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 2.707246e-02 | 1.567 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 2.707246e-02 | 1.567 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 2.547692e-02 | 1.594 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 2.547677e-02 | 1.594 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 2.463957e-02 | 1.608 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 2.560936e-02 | 1.592 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 2.651068e-02 | 1.577 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 2.764028e-02 | 1.558 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 2.365286e-02 | 1.626 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 2.417552e-02 | 1.617 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 2.516299e-02 | 1.599 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 2.450685e-02 | 1.611 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 2.680214e-02 | 1.572 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 2.547692e-02 | 1.594 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.547520e-02 | 1.594 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 2.547677e-02 | 1.594 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 2.765782e-02 | 1.558 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 2.765782e-02 | 1.558 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 2.823958e-02 | 1.549 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.828777e-02 | 1.548 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 2.857135e-02 | 1.544 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 2.874780e-02 | 1.541 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 2.874780e-02 | 1.541 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 2.906994e-02 | 1.537 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 2.978356e-02 | 1.526 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.978356e-02 | 1.526 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.005011e-02 | 1.522 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 3.026223e-02 | 1.519 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 3.078100e-02 | 1.512 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 3.116143e-02 | 1.506 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 3.186367e-02 | 1.497 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.186367e-02 | 1.497 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 3.210886e-02 | 1.493 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.312255e-02 | 1.480 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 3.312255e-02 | 1.480 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 3.328711e-02 | 1.478 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.361186e-02 | 1.474 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 3.380076e-02 | 1.471 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 3.380076e-02 | 1.471 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 3.388893e-02 | 1.470 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 3.388893e-02 | 1.470 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.413284e-02 | 1.467 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 3.448834e-02 | 1.462 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 3.554327e-02 | 1.449 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 3.604774e-02 | 1.443 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 3.674722e-02 | 1.435 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 3.713527e-02 | 1.430 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.079165e-02 | 1.389 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 4.079165e-02 | 1.389 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 4.211226e-02 | 1.376 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 3.807101e-02 | 1.419 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 3.807101e-02 | 1.419 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.807101e-02 | 1.419 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 4.076038e-02 | 1.390 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 4.236952e-02 | 1.373 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 4.319348e-02 | 1.365 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 4.603556e-02 | 1.337 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 4.475828e-02 | 1.349 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 4.475828e-02 | 1.349 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 3.837617e-02 | 1.416 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 3.913189e-02 | 1.407 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 4.327141e-02 | 1.364 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 4.593787e-02 | 1.338 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 3.722796e-02 | 1.429 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 4.310184e-02 | 1.366 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 3.795674e-02 | 1.421 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 4.064200e-02 | 1.391 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.780945e-02 | 1.422 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 4.023911e-02 | 1.395 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 4.020970e-02 | 1.396 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.722796e-02 | 1.429 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 4.203879e-02 | 1.376 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.777785e-02 | 1.423 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.120416e-02 | 1.385 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 4.689170e-02 | 1.329 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 4.820636e-02 | 1.317 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 4.864856e-02 | 1.313 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 4.870751e-02 | 1.312 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 4.870751e-02 | 1.312 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 4.870751e-02 | 1.312 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.870751e-02 | 1.312 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 4.938283e-02 | 1.306 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 4.963413e-02 | 1.304 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 4.966241e-02 | 1.304 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 4.970083e-02 | 1.304 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 4.978518e-02 | 1.303 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 4.978518e-02 | 1.303 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 5.129110e-02 | 1.290 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 5.129110e-02 | 1.290 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 5.150362e-02 | 1.288 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 5.152829e-02 | 1.288 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 5.152829e-02 | 1.288 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 5.277519e-02 | 1.278 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 5.541675e-02 | 1.256 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 5.640093e-02 | 1.249 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 5.640093e-02 | 1.249 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 5.650017e-02 | 1.248 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 5.650017e-02 | 1.248 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 5.713212e-02 | 1.243 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 5.713212e-02 | 1.243 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 5.730858e-02 | 1.242 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 5.730858e-02 | 1.242 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 5.805237e-02 | 1.236 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.827963e-02 | 1.234 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.827963e-02 | 1.234 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 5.827963e-02 | 1.234 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 5.827963e-02 | 1.234 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 5.827963e-02 | 1.234 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 6.077176e-02 | 1.216 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 6.217093e-02 | 1.206 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 6.227923e-02 | 1.206 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 6.227923e-02 | 1.206 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 6.227923e-02 | 1.206 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 6.269720e-02 | 1.203 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 6.269720e-02 | 1.203 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 6.269720e-02 | 1.203 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 6.269720e-02 | 1.203 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 6.269720e-02 | 1.203 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 6.269720e-02 | 1.203 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 6.271649e-02 | 1.203 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 6.290187e-02 | 1.201 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 6.290187e-02 | 1.201 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 6.328716e-02 | 1.199 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 6.328716e-02 | 1.199 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 6.328716e-02 | 1.199 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 6.328716e-02 | 1.199 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 6.328716e-02 | 1.199 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 6.328716e-02 | 1.199 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 6.328716e-02 | 1.199 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 6.328716e-02 | 1.199 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 6.341443e-02 | 1.198 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 6.375969e-02 | 1.195 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 7.582843e-02 | 1.120 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 7.582843e-02 | 1.120 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 7.582843e-02 | 1.120 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 7.582843e-02 | 1.120 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 7.582843e-02 | 1.120 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 7.582843e-02 | 1.120 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 7.582843e-02 | 1.120 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 7.582843e-02 | 1.120 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 6.617373e-02 | 1.179 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 6.617373e-02 | 1.179 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 6.617373e-02 | 1.179 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 8.653120e-02 | 1.063 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 7.871591e-02 | 1.104 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 7.871591e-02 | 1.104 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 7.025140e-02 | 1.153 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 7.025140e-02 | 1.153 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 8.474078e-02 | 1.072 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 8.474078e-02 | 1.072 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 8.474078e-02 | 1.072 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 8.474078e-02 | 1.072 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 7.405818e-02 | 1.130 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 6.566411e-02 | 1.183 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 7.351182e-02 | 1.134 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 8.496348e-02 | 1.071 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 8.278235e-02 | 1.082 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 6.968541e-02 | 1.157 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 6.521753e-02 | 1.186 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 6.521753e-02 | 1.186 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 7.489877e-02 | 1.126 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 8.281215e-02 | 1.082 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 8.281215e-02 | 1.082 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 8.281215e-02 | 1.082 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 7.840485e-02 | 1.106 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 6.935010e-02 | 1.159 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 7.929363e-02 | 1.101 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 6.686323e-02 | 1.175 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 7.559774e-02 | 1.121 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 7.871591e-02 | 1.104 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 8.337312e-02 | 1.079 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 8.653120e-02 | 1.063 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 8.623259e-02 | 1.064 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 7.582843e-02 | 1.120 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 8.030094e-02 | 1.095 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 8.310864e-02 | 1.080 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 7.675557e-02 | 1.115 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 6.569603e-02 | 1.182 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 7.806945e-02 | 1.108 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 7.491125e-02 | 1.125 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 7.871591e-02 | 1.104 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 7.489877e-02 | 1.126 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 8.665400e-02 | 1.062 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 8.665400e-02 | 1.062 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.665400e-02 | 1.062 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 8.665400e-02 | 1.062 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 8.710331e-02 | 1.060 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 8.710331e-02 | 1.060 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 8.719205e-02 | 1.060 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 8.719205e-02 | 1.060 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 8.719205e-02 | 1.060 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 8.719205e-02 | 1.060 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 8.719205e-02 | 1.060 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 8.755708e-02 | 1.058 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 8.949877e-02 | 1.048 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 9.025463e-02 | 1.045 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 9.031865e-02 | 1.044 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 9.031865e-02 | 1.044 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.123958e-02 | 1.040 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 9.127462e-02 | 1.040 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 9.128090e-02 | 1.040 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.396995e-01 | 0.855 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.396995e-01 | 0.855 | 0 | 0 |
| Drug resistance of ALK mutants | R-HSA-9700649 | 1.396995e-01 | 0.855 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.396995e-01 | 0.855 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.396995e-01 | 0.855 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.396995e-01 | 0.855 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.396995e-01 | 0.855 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 1.396995e-01 | 0.855 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.396995e-01 | 0.855 | 0 | 0 |
| crizotinib-resistant ALK mutants | R-HSA-9717326 | 1.396995e-01 | 0.855 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.396995e-01 | 0.855 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.396995e-01 | 0.855 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.396995e-01 | 0.855 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.396995e-01 | 0.855 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.396995e-01 | 0.855 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.396995e-01 | 0.855 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.396995e-01 | 0.855 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 1.396995e-01 | 0.855 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.396995e-01 | 0.855 | 0 | 0 |
| NVP-TAE684-resistant ALK mutants | R-HSA-9717301 | 1.396995e-01 | 0.855 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.396995e-01 | 0.855 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.396995e-01 | 0.855 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.396995e-01 | 0.855 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.396995e-01 | 0.855 | 0 | 0 |
| ceritinib-resistant ALK mutants | R-HSA-9717323 | 1.396995e-01 | 0.855 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.396995e-01 | 0.855 | 0 | 0 |
| brigatinib-resistant ALK mutants | R-HSA-9717319 | 1.396995e-01 | 0.855 | 0 | 0 |
| ASP-3026-resistant ALK mutants | R-HSA-9717264 | 1.396995e-01 | 0.855 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.396995e-01 | 0.855 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.396995e-01 | 0.855 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.396995e-01 | 0.855 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.396995e-01 | 0.855 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.396995e-01 | 0.855 | 0 | 0 |
| lorlatinib-resistant ALK mutants | R-HSA-9717329 | 1.396995e-01 | 0.855 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.396995e-01 | 0.855 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.396995e-01 | 0.855 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.396995e-01 | 0.855 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 1.396995e-01 | 0.855 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.396995e-01 | 0.855 | 0 | 0 |
| alectinib-resistant ALK mutants | R-HSA-9717316 | 1.396995e-01 | 0.855 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.396995e-01 | 0.855 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.396995e-01 | 0.855 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.396995e-01 | 0.855 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.396995e-01 | 0.855 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 1.225030e-01 | 0.912 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.225030e-01 | 0.912 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 1.225030e-01 | 0.912 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.212843e-01 | 0.916 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 1.095423e-01 | 0.960 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 1.095423e-01 | 0.960 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.095423e-01 | 0.960 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.095423e-01 | 0.960 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 1.095423e-01 | 0.960 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 9.671193e-02 | 1.015 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 9.671193e-02 | 1.015 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 9.671193e-02 | 1.015 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 9.671193e-02 | 1.015 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 9.671193e-02 | 1.015 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 9.671193e-02 | 1.015 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 9.671193e-02 | 1.015 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 1.349679e-01 | 0.870 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.349679e-01 | 0.870 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.349679e-01 | 0.870 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 1.165951e-01 | 0.933 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.165951e-01 | 0.933 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.165951e-01 | 0.933 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 1.165951e-01 | 0.933 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 1.165951e-01 | 0.933 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.007495e-01 | 0.997 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 1.007495e-01 | 0.997 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 1.382426e-01 | 0.859 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.382426e-01 | 0.859 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 1.182275e-01 | 0.927 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.015588e-01 | 0.993 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.015588e-01 | 0.993 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 1.371042e-01 | 0.863 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 1.371042e-01 | 0.863 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.171298e-01 | 0.931 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 1.171298e-01 | 0.931 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 1.005523e-01 | 0.998 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 1.338622e-01 | 0.873 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.338622e-01 | 0.873 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.579610e-02 | 1.019 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 9.579610e-02 | 1.019 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 1.112017e-01 | 0.954 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 1.295754e-01 | 0.887 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.295754e-01 | 0.887 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 1.033998e-01 | 0.985 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.197831e-01 | 0.922 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 1.147422e-01 | 0.940 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 1.001836e-01 | 0.999 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 1.324822e-01 | 0.878 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.367578e-01 | 0.864 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 1.082247e-01 | 0.966 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 9.931900e-02 | 1.003 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 9.931900e-02 | 1.003 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 1.392097e-01 | 0.856 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 1.392097e-01 | 0.856 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 1.367578e-01 | 0.864 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.015588e-01 | 0.993 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 1.163606e-01 | 0.934 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.392097e-01 | 0.856 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 1.097603e-01 | 0.960 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 1.371937e-01 | 0.863 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 1.197831e-01 | 0.922 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 1.349679e-01 | 0.870 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 9.848636e-02 | 1.007 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 1.048960e-01 | 0.979 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 9.888833e-02 | 1.005 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.225030e-01 | 0.912 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 1.074057e-01 | 0.969 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.151070e-01 | 0.939 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 1.027978e-01 | 0.988 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 1.145672e-01 | 0.941 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 9.579610e-02 | 1.019 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 9.671193e-02 | 1.015 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 9.623224e-02 | 1.017 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.201365e-01 | 0.920 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.074057e-01 | 0.969 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.080969e-01 | 0.966 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.402204e-01 | 0.853 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 1.007495e-01 | 0.997 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.366156e-01 | 0.864 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 9.671193e-02 | 1.015 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.212843e-01 | 0.916 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 1.001836e-01 | 0.999 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 9.589851e-02 | 1.018 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 1.201365e-01 | 0.920 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 1.295754e-01 | 0.887 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 1.212843e-01 | 0.916 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.095423e-01 | 0.960 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 1.171298e-01 | 0.931 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 9.579610e-02 | 1.019 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 1.258756e-01 | 0.900 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.005461e-01 | 0.998 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.136983e-01 | 0.944 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.337122e-01 | 0.874 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 1.182275e-01 | 0.927 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.402373e-01 | 0.853 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.104863e-01 | 0.957 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 1.392097e-01 | 0.856 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 1.371042e-01 | 0.863 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 9.623224e-02 | 1.017 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.349679e-01 | 0.870 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.096442e-01 | 0.960 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 1.407048e-01 | 0.852 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 1.410888e-01 | 0.851 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 1.443143e-01 | 0.841 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.467762e-01 | 0.833 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.482583e-01 | 0.829 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 1.517004e-01 | 0.819 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 1.517004e-01 | 0.819 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.527814e-01 | 0.816 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 1.527814e-01 | 0.816 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.538159e-01 | 0.813 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 1.544489e-01 | 0.811 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 1.555078e-01 | 0.808 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 1.555078e-01 | 0.808 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 1.555078e-01 | 0.808 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 1.555078e-01 | 0.808 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 1.572908e-01 | 0.803 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 1.572908e-01 | 0.803 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 1.575811e-01 | 0.802 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.599025e-01 | 0.796 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 1.613458e-01 | 0.792 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 1.613458e-01 | 0.792 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.615048e-01 | 0.792 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 1.615048e-01 | 0.792 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.615048e-01 | 0.792 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.615048e-01 | 0.792 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.624194e-01 | 0.789 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.625259e-01 | 0.789 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 1.625259e-01 | 0.789 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.625259e-01 | 0.789 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 1.645239e-01 | 0.784 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.645239e-01 | 0.784 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.645239e-01 | 0.784 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 1.646399e-01 | 0.783 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 1.667391e-01 | 0.778 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 1.704650e-01 | 0.768 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.704650e-01 | 0.768 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 1.704650e-01 | 0.768 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.704650e-01 | 0.768 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.704650e-01 | 0.768 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 1.710544e-01 | 0.767 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 1.739722e-01 | 0.760 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 1.741757e-01 | 0.759 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 1.741757e-01 | 0.759 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 1.741757e-01 | 0.759 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 1.741757e-01 | 0.759 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.765917e-01 | 0.753 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 1.765917e-01 | 0.753 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 1.769463e-01 | 0.752 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 1.786836e-01 | 0.748 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.786836e-01 | 0.748 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.789930e-01 | 0.747 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.801578e-01 | 0.744 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 1.801578e-01 | 0.744 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 1.801578e-01 | 0.744 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.801578e-01 | 0.744 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.805675e-01 | 0.743 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 1.812961e-01 | 0.742 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 1.812961e-01 | 0.742 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 1.812961e-01 | 0.742 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.817520e-01 | 0.741 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 1.831982e-01 | 0.737 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 1.835504e-01 | 0.736 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 1.849186e-01 | 0.733 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.862111e-01 | 0.730 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 1.872153e-01 | 0.728 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 1.872153e-01 | 0.728 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 1.872153e-01 | 0.728 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 1.877003e-01 | 0.727 | 0 | 0 |
| Activation, translocation and oligomerization of BAX | R-HSA-114294 | 2.598900e-01 | 0.585 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.598900e-01 | 0.585 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.598900e-01 | 0.585 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.598900e-01 | 0.585 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.598900e-01 | 0.585 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.598900e-01 | 0.585 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.598900e-01 | 0.585 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 2.598900e-01 | 0.585 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 2.598900e-01 | 0.585 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.598900e-01 | 0.585 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 2.598900e-01 | 0.585 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 2.598900e-01 | 0.585 | 0 | 0 |
| SARS-CoV-1 targets PDZ proteins in cell-cell junction | R-HSA-9692912 | 2.598900e-01 | 0.585 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.598900e-01 | 0.585 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 2.285405e-01 | 0.641 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 2.285405e-01 | 0.641 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.285405e-01 | 0.641 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 3.632949e-01 | 0.440 | 0 | 0 |
| Signaling by FGFR3 fusions in cancer | R-HSA-8853334 | 3.632949e-01 | 0.440 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 3.632949e-01 | 0.440 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 3.632949e-01 | 0.440 | 0 | 0 |
| t(4;14) translocations of FGFR3 | R-HSA-2033515 | 3.632949e-01 | 0.440 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 3.632949e-01 | 0.440 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 3.632949e-01 | 0.440 | 0 | 0 |
| Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) | R-HSA-5619048 | 3.632949e-01 | 0.440 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 3.632949e-01 | 0.440 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 3.632949e-01 | 0.440 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 3.632949e-01 | 0.440 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 3.632949e-01 | 0.440 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.632949e-01 | 0.440 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 1.922923e-01 | 0.716 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 1.922923e-01 | 0.716 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 1.922923e-01 | 0.716 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.922923e-01 | 0.716 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 1.922923e-01 | 0.716 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 2.838377e-01 | 0.547 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 2.838377e-01 | 0.547 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 2.838377e-01 | 0.547 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 2.838377e-01 | 0.547 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 2.838377e-01 | 0.547 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 2.309580e-01 | 0.636 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 2.309580e-01 | 0.636 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 2.309580e-01 | 0.636 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 2.309580e-01 | 0.636 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.919063e-01 | 0.717 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 1.919063e-01 | 0.717 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 2.708666e-01 | 0.567 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 2.708666e-01 | 0.567 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 2.708666e-01 | 0.567 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 2.708666e-01 | 0.567 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 2.708666e-01 | 0.567 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 2.708666e-01 | 0.567 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 3.387463e-01 | 0.470 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 3.387463e-01 | 0.470 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 3.387463e-01 | 0.470 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 3.387463e-01 | 0.470 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 3.387463e-01 | 0.470 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 3.387463e-01 | 0.470 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 3.387463e-01 | 0.470 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 3.387463e-01 | 0.470 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 2.548341e-01 | 0.594 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 2.548341e-01 | 0.594 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 2.548341e-01 | 0.594 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.011662e-01 | 0.696 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 3.114369e-01 | 0.507 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.392054e-01 | 0.621 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 1.904160e-01 | 0.720 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 1.904160e-01 | 0.720 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.246130e-01 | 0.649 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 2.877333e-01 | 0.541 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 2.111313e-01 | 0.675 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 2.488916e-01 | 0.604 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 2.488916e-01 | 0.604 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 2.488916e-01 | 0.604 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.326312e-01 | 0.633 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.326312e-01 | 0.633 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 3.211748e-01 | 0.493 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 3.211748e-01 | 0.493 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 3.211748e-01 | 0.493 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 2.089683e-01 | 0.680 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 2.775942e-01 | 0.557 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 3.246887e-01 | 0.489 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 3.008546e-01 | 0.522 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.619335e-01 | 0.582 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 3.484212e-01 | 0.458 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 2.971366e-01 | 0.527 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 2.590184e-01 | 0.587 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 2.716193e-01 | 0.566 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 3.706860e-01 | 0.431 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 3.191420e-01 | 0.496 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 3.708141e-01 | 0.431 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 3.537655e-01 | 0.451 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 2.046524e-01 | 0.689 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 2.176088e-01 | 0.662 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 2.170353e-01 | 0.663 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 3.189045e-01 | 0.496 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 3.725254e-01 | 0.429 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 3.447111e-01 | 0.463 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 3.191420e-01 | 0.496 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 3.515839e-01 | 0.454 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.576789e-01 | 0.589 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 2.801690e-01 | 0.553 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 2.617185e-01 | 0.582 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 2.326312e-01 | 0.633 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.794785e-01 | 0.554 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 2.418828e-01 | 0.616 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 2.838377e-01 | 0.547 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 2.807977e-01 | 0.552 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 3.114369e-01 | 0.507 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 1.997656e-01 | 0.699 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 3.368832e-01 | 0.473 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.179708e-01 | 0.662 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 3.253477e-01 | 0.488 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 1.922923e-01 | 0.716 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 2.838377e-01 | 0.547 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 3.114369e-01 | 0.507 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 2.392054e-01 | 0.621 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 3.484212e-01 | 0.458 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 3.448808e-01 | 0.462 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 2.032978e-01 | 0.692 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 2.708666e-01 | 0.567 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 3.725254e-01 | 0.429 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 2.309580e-01 | 0.636 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.904160e-01 | 0.720 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 2.031176e-01 | 0.692 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 2.227848e-01 | 0.652 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 3.211748e-01 | 0.493 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 2.956591e-01 | 0.529 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 3.596295e-01 | 0.444 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 3.569137e-01 | 0.447 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 2.089683e-01 | 0.680 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 2.738655e-01 | 0.562 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 3.520197e-01 | 0.453 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 2.168271e-01 | 0.664 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 3.140405e-01 | 0.503 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 3.174749e-01 | 0.498 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 3.520197e-01 | 0.453 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 3.695165e-01 | 0.432 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 2.975028e-01 | 0.527 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 2.838377e-01 | 0.547 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 3.387463e-01 | 0.470 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 2.877333e-01 | 0.541 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 3.548702e-01 | 0.450 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 3.548702e-01 | 0.450 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 2.282524e-01 | 0.642 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 3.001892e-01 | 0.523 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 3.725254e-01 | 0.429 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 2.738655e-01 | 0.562 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 2.294287e-01 | 0.639 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 2.868018e-01 | 0.542 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 2.616080e-01 | 0.582 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 3.426876e-01 | 0.465 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 2.708666e-01 | 0.567 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 3.387463e-01 | 0.470 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.111313e-01 | 0.675 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 3.779748e-01 | 0.423 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 3.537655e-01 | 0.451 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.229282e-01 | 0.652 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 3.001892e-01 | 0.523 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 2.246130e-01 | 0.649 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 2.883159e-01 | 0.540 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 3.114369e-01 | 0.507 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 2.227239e-01 | 0.652 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 3.246887e-01 | 0.489 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 2.768886e-01 | 0.558 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 3.619660e-01 | 0.441 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 2.616080e-01 | 0.582 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.670995e-01 | 0.573 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 3.211748e-01 | 0.493 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 3.448808e-01 | 0.462 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 2.956591e-01 | 0.529 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 3.071628e-01 | 0.513 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 3.001892e-01 | 0.523 | 0 | 0 |
| Depurination | R-HSA-73927 | 3.671747e-01 | 0.435 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 2.309345e-01 | 0.637 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 2.049978e-01 | 0.688 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 3.297186e-01 | 0.482 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.598900e-01 | 0.585 | 0 | 0 |
| SDK interactions | R-HSA-373756 | 2.598900e-01 | 0.585 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 2.285405e-01 | 0.641 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 3.632949e-01 | 0.440 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 2.838377e-01 | 0.547 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 3.387463e-01 | 0.470 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 3.387463e-01 | 0.470 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 2.877333e-01 | 0.541 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 2.179708e-01 | 0.662 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 1.924788e-01 | 0.716 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 2.227239e-01 | 0.652 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 3.779748e-01 | 0.423 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 2.852529e-01 | 0.545 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.053921e-01 | 0.687 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 3.706860e-01 | 0.431 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 2.179708e-01 | 0.662 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 2.611003e-01 | 0.583 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 3.156268e-01 | 0.501 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 1.933417e-01 | 0.714 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 2.906696e-01 | 0.537 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 3.779748e-01 | 0.423 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 3.586603e-01 | 0.445 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 1.922923e-01 | 0.716 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 1.922923e-01 | 0.716 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 3.387463e-01 | 0.470 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 3.211748e-01 | 0.493 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 3.246887e-01 | 0.489 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 3.539996e-01 | 0.451 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 3.205388e-01 | 0.494 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.361314e-01 | 0.627 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.922923e-01 | 0.716 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 3.706860e-01 | 0.431 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 3.632949e-01 | 0.440 | 0 | 0 |
| Inhibition of membrane repair | R-HSA-9635644 | 3.632949e-01 | 0.440 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 2.838377e-01 | 0.547 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 2.309580e-01 | 0.636 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 2.877333e-01 | 0.541 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 2.179708e-01 | 0.662 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 2.584376e-01 | 0.588 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 2.172602e-01 | 0.663 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 3.472799e-01 | 0.459 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.246130e-01 | 0.649 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 2.605427e-01 | 0.584 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 2.605427e-01 | 0.584 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 2.430256e-01 | 0.614 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 2.768886e-01 | 0.558 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.227803e-01 | 0.491 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 3.632949e-01 | 0.440 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 2.838377e-01 | 0.547 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 2.309580e-01 | 0.636 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 3.548702e-01 | 0.450 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 3.227803e-01 | 0.491 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.448808e-01 | 0.462 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 3.411526e-01 | 0.467 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 3.411526e-01 | 0.467 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 3.779748e-01 | 0.423 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.440166e-01 | 0.613 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 2.448814e-01 | 0.611 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 2.448814e-01 | 0.611 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 3.227803e-01 | 0.491 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 2.988563e-01 | 0.525 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 3.387463e-01 | 0.470 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 3.521532e-01 | 0.453 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 3.211748e-01 | 0.493 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 2.584376e-01 | 0.588 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 2.794785e-01 | 0.554 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.252172e-01 | 0.647 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 2.158364e-01 | 0.666 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 3.725254e-01 | 0.429 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 3.598426e-01 | 0.444 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 3.387463e-01 | 0.470 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 2.794785e-01 | 0.554 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 3.808128e-01 | 0.419 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 3.808128e-01 | 0.419 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 3.834128e-01 | 0.416 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 3.834128e-01 | 0.416 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 3.842537e-01 | 0.415 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 3.872045e-01 | 0.412 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 3.885541e-01 | 0.411 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 3.885541e-01 | 0.411 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 3.885541e-01 | 0.411 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 3.885541e-01 | 0.411 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 3.885541e-01 | 0.411 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 3.885541e-01 | 0.411 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 3.885541e-01 | 0.411 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 3.895844e-01 | 0.409 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 3.922960e-01 | 0.406 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 3.922960e-01 | 0.406 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 3.922960e-01 | 0.406 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 3.922960e-01 | 0.406 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 3.922960e-01 | 0.406 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 3.925682e-01 | 0.406 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 3.925682e-01 | 0.406 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 3.925682e-01 | 0.406 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 3.925682e-01 | 0.406 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 3.925682e-01 | 0.406 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 3.964479e-01 | 0.402 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 3.967132e-01 | 0.402 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 3.967132e-01 | 0.402 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.039361e-01 | 0.394 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.039361e-01 | 0.394 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 4.043956e-01 | 0.393 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 4.043956e-01 | 0.393 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.083035e-01 | 0.389 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 4.120340e-01 | 0.385 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.136759e-01 | 0.383 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 4.151841e-01 | 0.382 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 4.163049e-01 | 0.381 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 4.208916e-01 | 0.376 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 4.212680e-01 | 0.375 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 4.219862e-01 | 0.375 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 4.219862e-01 | 0.375 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.249690e-01 | 0.372 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 4.249690e-01 | 0.372 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.249690e-01 | 0.372 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 4.249690e-01 | 0.372 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 4.307286e-01 | 0.366 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 4.307286e-01 | 0.366 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 4.307286e-01 | 0.366 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 4.323028e-01 | 0.364 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 4.323028e-01 | 0.364 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 4.323028e-01 | 0.364 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 4.323028e-01 | 0.364 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 4.323028e-01 | 0.364 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 4.323028e-01 | 0.364 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 4.323028e-01 | 0.364 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 4.323028e-01 | 0.364 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 4.323028e-01 | 0.364 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 4.323028e-01 | 0.364 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 4.344509e-01 | 0.362 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 4.344509e-01 | 0.362 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 4.353990e-01 | 0.361 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 4.418882e-01 | 0.355 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 4.430402e-01 | 0.354 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 4.437950e-01 | 0.353 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 4.437950e-01 | 0.353 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 4.437950e-01 | 0.353 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 4.437950e-01 | 0.353 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 4.437950e-01 | 0.353 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 4.437950e-01 | 0.353 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 4.437950e-01 | 0.353 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 4.437950e-01 | 0.353 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 4.437950e-01 | 0.353 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 4.437950e-01 | 0.353 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 4.437950e-01 | 0.353 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 4.437950e-01 | 0.353 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 4.448741e-01 | 0.352 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 4.459544e-01 | 0.351 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 4.521812e-01 | 0.345 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 4.522576e-01 | 0.345 | 0 | 0 |
| Interaction between PHLDA1 and AURKA | R-HSA-8854521 | 4.522576e-01 | 0.345 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 4.522576e-01 | 0.345 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 4.522576e-01 | 0.345 | 0 | 0 |
| Defective OPLAH causes OPLAHD | R-HSA-5578998 | 4.522576e-01 | 0.345 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 4.522576e-01 | 0.345 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 4.522576e-01 | 0.345 | 0 | 0 |
| Defective visual phototransduction due to STRA6 loss of function | R-HSA-9918449 | 4.522576e-01 | 0.345 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 4.522576e-01 | 0.345 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 4.522576e-01 | 0.345 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 4.522576e-01 | 0.345 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 4.522576e-01 | 0.345 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 4.522576e-01 | 0.345 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.535322e-01 | 0.343 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 4.549532e-01 | 0.342 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 4.549532e-01 | 0.342 | 0 | 0 |
| PKA activation | R-HSA-163615 | 4.549532e-01 | 0.342 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 4.549532e-01 | 0.342 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 4.549532e-01 | 0.342 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 4.549532e-01 | 0.342 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 4.549532e-01 | 0.342 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 4.559463e-01 | 0.341 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 4.567654e-01 | 0.340 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 4.567654e-01 | 0.340 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 4.567654e-01 | 0.340 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 4.568636e-01 | 0.340 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 4.568636e-01 | 0.340 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 4.668360e-01 | 0.331 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 4.688332e-01 | 0.329 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 4.706549e-01 | 0.327 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 4.706549e-01 | 0.327 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 4.710434e-01 | 0.327 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 4.710434e-01 | 0.327 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 4.710434e-01 | 0.327 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 4.710434e-01 | 0.327 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 4.710434e-01 | 0.327 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 4.710434e-01 | 0.327 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 4.710434e-01 | 0.327 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 4.739028e-01 | 0.324 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 4.834586e-01 | 0.316 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 4.872691e-01 | 0.312 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 4.872691e-01 | 0.312 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 4.872691e-01 | 0.312 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 4.872691e-01 | 0.312 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 4.925115e-01 | 0.308 | 0 | 0 |
| Immune System | R-HSA-168256 | 4.925229e-01 | 0.308 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 4.927712e-01 | 0.307 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 4.927712e-01 | 0.307 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 4.927712e-01 | 0.307 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 4.927712e-01 | 0.307 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 4.927712e-01 | 0.307 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 4.927712e-01 | 0.307 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 4.927712e-01 | 0.307 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 4.927712e-01 | 0.307 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 4.927712e-01 | 0.307 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 4.944181e-01 | 0.306 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 4.951746e-01 | 0.305 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 4.966454e-01 | 0.304 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 4.966454e-01 | 0.304 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 4.966454e-01 | 0.304 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 4.989347e-01 | 0.302 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 4.989347e-01 | 0.302 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 5.008284e-01 | 0.300 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 5.081776e-01 | 0.294 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 5.085374e-01 | 0.294 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 5.085374e-01 | 0.294 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 5.085374e-01 | 0.294 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 5.085374e-01 | 0.294 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 5.085374e-01 | 0.294 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 5.092966e-01 | 0.293 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.132825e-01 | 0.290 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 5.158218e-01 | 0.288 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 5.158218e-01 | 0.288 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 5.187746e-01 | 0.285 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 5.266161e-01 | 0.279 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 5.266161e-01 | 0.279 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 5.266161e-01 | 0.279 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 5.283377e-01 | 0.277 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 5.287946e-01 | 0.277 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 5.287946e-01 | 0.277 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 5.287946e-01 | 0.277 | 0 | 0 |
| Defective gamma-carboxylation of F9 | R-HSA-9673240 | 5.287946e-01 | 0.277 | 0 | 0 |
| Defective DPM2 causes DPM2-CDG | R-HSA-4719377 | 5.287946e-01 | 0.277 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 5.287946e-01 | 0.277 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 5.287946e-01 | 0.277 | 0 | 0 |
| Defective DPM1 causes DPM1-CDG | R-HSA-4717374 | 5.287946e-01 | 0.277 | 0 | 0 |
| Defective DPM3 causes DPM3-CDG | R-HSA-4719360 | 5.287946e-01 | 0.277 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 5.287946e-01 | 0.277 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.287946e-01 | 0.277 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 5.287946e-01 | 0.277 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 5.287946e-01 | 0.277 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 5.287946e-01 | 0.277 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 5.287946e-01 | 0.277 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 5.305975e-01 | 0.275 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 5.328888e-01 | 0.273 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 5.331114e-01 | 0.273 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 5.331114e-01 | 0.273 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 5.332772e-01 | 0.273 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 5.336423e-01 | 0.273 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 5.389242e-01 | 0.268 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 5.389242e-01 | 0.268 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 5.389242e-01 | 0.268 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 5.389242e-01 | 0.268 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 5.389242e-01 | 0.268 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 5.389242e-01 | 0.268 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 5.389242e-01 | 0.268 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 5.389242e-01 | 0.268 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 5.389242e-01 | 0.268 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 5.389242e-01 | 0.268 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 5.437481e-01 | 0.265 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 5.437481e-01 | 0.265 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 5.445879e-01 | 0.264 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 5.445879e-01 | 0.264 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 5.445879e-01 | 0.264 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 5.445879e-01 | 0.264 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 5.445879e-01 | 0.264 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 5.445879e-01 | 0.264 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 5.445879e-01 | 0.264 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 5.471636e-01 | 0.262 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 5.483001e-01 | 0.261 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 5.493364e-01 | 0.260 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 5.493364e-01 | 0.260 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 5.493364e-01 | 0.260 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 5.536024e-01 | 0.257 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 5.536024e-01 | 0.257 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 5.548804e-01 | 0.256 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 5.578192e-01 | 0.254 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 5.611974e-01 | 0.251 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 5.611974e-01 | 0.251 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 5.646503e-01 | 0.248 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 5.668986e-01 | 0.246 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 5.727230e-01 | 0.242 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 5.788460e-01 | 0.237 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 5.788460e-01 | 0.237 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 5.788460e-01 | 0.237 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 5.788460e-01 | 0.237 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 5.790476e-01 | 0.237 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 5.790476e-01 | 0.237 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 5.790476e-01 | 0.237 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 5.790476e-01 | 0.237 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 5.790476e-01 | 0.237 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 5.798115e-01 | 0.237 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 5.813367e-01 | 0.236 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 5.820868e-01 | 0.235 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 5.820868e-01 | 0.235 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 5.820868e-01 | 0.235 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 5.820868e-01 | 0.235 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 5.820868e-01 | 0.235 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 5.820868e-01 | 0.235 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 5.820868e-01 | 0.235 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 5.851215e-01 | 0.233 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 5.851215e-01 | 0.233 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 5.873987e-01 | 0.231 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 5.934526e-01 | 0.227 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 5.946407e-01 | 0.226 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 5.946407e-01 | 0.226 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 5.946407e-01 | 0.226 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 5.946407e-01 | 0.226 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 5.946407e-01 | 0.226 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 5.946407e-01 | 0.226 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 5.946407e-01 | 0.226 | 0 | 0 |
| Signaling by LRP5 mutants | R-HSA-5339717 | 5.946407e-01 | 0.226 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 5.946407e-01 | 0.226 | 0 | 0 |
| MDK and PTN in ALK signaling | R-HSA-9851151 | 5.946407e-01 | 0.226 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 5.946407e-01 | 0.226 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 5.946407e-01 | 0.226 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 5.946407e-01 | 0.226 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 5.946407e-01 | 0.226 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 6.044734e-01 | 0.219 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 6.044734e-01 | 0.219 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 6.051747e-01 | 0.218 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 6.051747e-01 | 0.218 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 6.072177e-01 | 0.217 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 6.072177e-01 | 0.217 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 6.072177e-01 | 0.217 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 6.072177e-01 | 0.217 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 6.083636e-01 | 0.216 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.111429e-01 | 0.214 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 6.118134e-01 | 0.213 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 6.118134e-01 | 0.213 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 6.118134e-01 | 0.213 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 6.118134e-01 | 0.213 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 6.156630e-01 | 0.211 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 6.203244e-01 | 0.207 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 6.203244e-01 | 0.207 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 6.221935e-01 | 0.206 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 6.221935e-01 | 0.206 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 6.221935e-01 | 0.206 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 6.221935e-01 | 0.206 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 6.221935e-01 | 0.206 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 6.221935e-01 | 0.206 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 6.245805e-01 | 0.204 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 6.268945e-01 | 0.203 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 6.283822e-01 | 0.202 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 6.296369e-01 | 0.201 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 6.296369e-01 | 0.201 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 6.343870e-01 | 0.198 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 6.343870e-01 | 0.198 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 6.413134e-01 | 0.193 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 6.416380e-01 | 0.193 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 6.416380e-01 | 0.193 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 6.428200e-01 | 0.192 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 6.428200e-01 | 0.192 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 6.445261e-01 | 0.191 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 6.455512e-01 | 0.190 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 6.472441e-01 | 0.189 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 6.482283e-01 | 0.188 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 6.512887e-01 | 0.186 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 6.512887e-01 | 0.186 | 0 | 0 |
| FGFR1c and Klotho ligand binding and activation | R-HSA-190374 | 6.512887e-01 | 0.186 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 6.512887e-01 | 0.186 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 6.512887e-01 | 0.186 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 6.512887e-01 | 0.186 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 6.512887e-01 | 0.186 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 6.512887e-01 | 0.186 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 6.512887e-01 | 0.186 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 6.512887e-01 | 0.186 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 6.512887e-01 | 0.186 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 6.512887e-01 | 0.186 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 6.512887e-01 | 0.186 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 6.512887e-01 | 0.186 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 6.513299e-01 | 0.186 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 6.525812e-01 | 0.185 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 6.531549e-01 | 0.185 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 6.549064e-01 | 0.184 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 6.549064e-01 | 0.184 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 6.576015e-01 | 0.182 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 6.576015e-01 | 0.182 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 6.592555e-01 | 0.181 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 6.592555e-01 | 0.181 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 6.592555e-01 | 0.181 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 6.592555e-01 | 0.181 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 6.592555e-01 | 0.181 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 6.592555e-01 | 0.181 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 6.603087e-01 | 0.180 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 6.603087e-01 | 0.180 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 6.603087e-01 | 0.180 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 6.603087e-01 | 0.180 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 6.650849e-01 | 0.177 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 6.695289e-01 | 0.174 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 6.695289e-01 | 0.174 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 6.695289e-01 | 0.174 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 6.712616e-01 | 0.173 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 6.720347e-01 | 0.173 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 6.720347e-01 | 0.173 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 6.720347e-01 | 0.173 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 6.798280e-01 | 0.168 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 6.839444e-01 | 0.165 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 6.849546e-01 | 0.164 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 6.849546e-01 | 0.164 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 6.849546e-01 | 0.164 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 6.849546e-01 | 0.164 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 6.849546e-01 | 0.164 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 6.895215e-01 | 0.161 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 6.931827e-01 | 0.159 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 6.931827e-01 | 0.159 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 6.931827e-01 | 0.159 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 6.931827e-01 | 0.159 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 6.931827e-01 | 0.159 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 6.933403e-01 | 0.159 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 6.933403e-01 | 0.159 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 6.933403e-01 | 0.159 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 6.933403e-01 | 0.159 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 6.933403e-01 | 0.159 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 6.933403e-01 | 0.159 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 6.933403e-01 | 0.159 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 6.933403e-01 | 0.159 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 6.933403e-01 | 0.159 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 6.933403e-01 | 0.159 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 6.970659e-01 | 0.157 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 6.972428e-01 | 0.157 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 6.994522e-01 | 0.155 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 6.994522e-01 | 0.155 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 6.994522e-01 | 0.155 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 7.000231e-01 | 0.155 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 7.000231e-01 | 0.155 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 7.000231e-01 | 0.155 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 7.000231e-01 | 0.155 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 7.000231e-01 | 0.155 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 7.000231e-01 | 0.155 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 7.000231e-01 | 0.155 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 7.000231e-01 | 0.155 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 7.000231e-01 | 0.155 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 7.000231e-01 | 0.155 | 0 | 0 |
| Synthesis of dolichyl-phosphate mannose | R-HSA-162699 | 7.000231e-01 | 0.155 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 7.000231e-01 | 0.155 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 7.000231e-01 | 0.155 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 7.000231e-01 | 0.155 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 7.000231e-01 | 0.155 | 0 | 0 |
| Threonine catabolism | R-HSA-8849175 | 7.000231e-01 | 0.155 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 7.000231e-01 | 0.155 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 7.000231e-01 | 0.155 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 7.000231e-01 | 0.155 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 7.000231e-01 | 0.155 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 7.000231e-01 | 0.155 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 7.028104e-01 | 0.153 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 7.083118e-01 | 0.150 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 7.090807e-01 | 0.149 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 7.186373e-01 | 0.143 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 7.217002e-01 | 0.142 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 7.244380e-01 | 0.140 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 7.245563e-01 | 0.140 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 7.245563e-01 | 0.140 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.250896e-01 | 0.140 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 7.285966e-01 | 0.138 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 7.302268e-01 | 0.137 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 7.303807e-01 | 0.136 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 7.303807e-01 | 0.136 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 7.363374e-01 | 0.133 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 7.373054e-01 | 0.132 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 7.373054e-01 | 0.132 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 7.396186e-01 | 0.131 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 7.419491e-01 | 0.130 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 7.419491e-01 | 0.130 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 7.419491e-01 | 0.130 | 0 | 0 |
| Defective CHST3 causes SEDCJD | R-HSA-3595172 | 7.419491e-01 | 0.130 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 7.419491e-01 | 0.130 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 7.419491e-01 | 0.130 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 7.419491e-01 | 0.130 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 7.419491e-01 | 0.130 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 7.419491e-01 | 0.130 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 7.419491e-01 | 0.130 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 7.419491e-01 | 0.130 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 7.419491e-01 | 0.130 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 7.419491e-01 | 0.130 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 7.419491e-01 | 0.130 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 7.438435e-01 | 0.129 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 7.489823e-01 | 0.126 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 7.489823e-01 | 0.126 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 7.489823e-01 | 0.126 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 7.489823e-01 | 0.126 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 7.489823e-01 | 0.126 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 7.489823e-01 | 0.126 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 7.515112e-01 | 0.124 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 7.530393e-01 | 0.123 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 7.530393e-01 | 0.123 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 7.530393e-01 | 0.123 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 7.558237e-01 | 0.122 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 7.615434e-01 | 0.118 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 7.618524e-01 | 0.118 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 7.677185e-01 | 0.115 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 7.707095e-01 | 0.113 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 7.707095e-01 | 0.113 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 7.711804e-01 | 0.113 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 7.711804e-01 | 0.113 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 7.724397e-01 | 0.112 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 7.735104e-01 | 0.112 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 7.764186e-01 | 0.110 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 7.780173e-01 | 0.109 | 0 | 0 |
| Defective CHSY1 causes TPBS | R-HSA-3595177 | 7.780173e-01 | 0.109 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 7.780173e-01 | 0.109 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 7.780173e-01 | 0.109 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 7.780173e-01 | 0.109 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 7.780173e-01 | 0.109 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 7.780173e-01 | 0.109 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 7.780173e-01 | 0.109 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 7.780173e-01 | 0.109 | 0 | 0 |
| Reuptake of GABA | R-HSA-888593 | 7.780173e-01 | 0.109 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 7.780173e-01 | 0.109 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 7.780173e-01 | 0.109 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 7.780173e-01 | 0.109 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 7.780173e-01 | 0.109 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 7.780173e-01 | 0.109 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 7.780173e-01 | 0.109 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 7.780173e-01 | 0.109 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 7.789435e-01 | 0.108 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 7.789435e-01 | 0.108 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 7.789435e-01 | 0.108 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 7.789435e-01 | 0.108 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 7.789435e-01 | 0.108 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 7.789435e-01 | 0.108 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 7.789435e-01 | 0.108 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 7.789435e-01 | 0.108 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 7.832673e-01 | 0.106 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 7.890203e-01 | 0.103 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 7.917453e-01 | 0.101 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 7.917453e-01 | 0.101 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 7.917453e-01 | 0.101 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 7.917453e-01 | 0.101 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 7.962795e-01 | 0.099 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 8.005182e-01 | 0.097 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 8.024332e-01 | 0.096 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 8.024332e-01 | 0.096 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 8.024332e-01 | 0.096 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 8.024332e-01 | 0.096 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 8.054735e-01 | 0.094 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 8.054735e-01 | 0.094 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 8.061410e-01 | 0.094 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 8.069025e-01 | 0.093 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 8.090461e-01 | 0.092 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 8.090461e-01 | 0.092 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 8.090461e-01 | 0.092 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 8.090461e-01 | 0.092 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 8.090461e-01 | 0.092 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 8.090461e-01 | 0.092 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 8.090461e-01 | 0.092 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 8.090461e-01 | 0.092 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 8.090461e-01 | 0.092 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 8.097262e-01 | 0.092 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 8.204340e-01 | 0.086 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 8.220943e-01 | 0.085 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 8.221128e-01 | 0.085 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 8.236772e-01 | 0.084 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 8.236772e-01 | 0.084 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 8.236772e-01 | 0.084 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 8.236772e-01 | 0.084 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 8.236772e-01 | 0.084 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 8.236772e-01 | 0.084 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.236772e-01 | 0.084 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 8.236772e-01 | 0.084 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 8.236772e-01 | 0.084 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 8.249044e-01 | 0.084 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 8.275871e-01 | 0.082 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 8.275985e-01 | 0.082 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 8.282594e-01 | 0.082 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 8.282594e-01 | 0.082 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 8.282594e-01 | 0.082 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 8.282594e-01 | 0.082 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 8.282594e-01 | 0.082 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 8.352617e-01 | 0.078 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 8.357391e-01 | 0.078 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 8.357391e-01 | 0.078 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 8.357391e-01 | 0.078 | 0 | 0 |
| Enzymatic degradation of Dopamine by monoamine oxidase | R-HSA-379398 | 8.357391e-01 | 0.078 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 8.357391e-01 | 0.078 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 8.357391e-01 | 0.078 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 8.357391e-01 | 0.078 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 8.357391e-01 | 0.078 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 8.357391e-01 | 0.078 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 8.357391e-01 | 0.078 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 8.369810e-01 | 0.077 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 8.428441e-01 | 0.074 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 8.428441e-01 | 0.074 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 8.428441e-01 | 0.074 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 8.428441e-01 | 0.074 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 8.428441e-01 | 0.074 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 8.428441e-01 | 0.074 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 8.428441e-01 | 0.074 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 8.428441e-01 | 0.074 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 8.443634e-01 | 0.073 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.443634e-01 | 0.073 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 8.443634e-01 | 0.073 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 8.452324e-01 | 0.073 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 8.452324e-01 | 0.073 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 8.454646e-01 | 0.073 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 8.501964e-01 | 0.070 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 8.563909e-01 | 0.067 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 8.566289e-01 | 0.067 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 8.575561e-01 | 0.067 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 8.587021e-01 | 0.066 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 8.587021e-01 | 0.066 | 0 | 0 |
| Enzymatic degradation of dopamine by COMT | R-HSA-379397 | 8.587021e-01 | 0.066 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 8.587021e-01 | 0.066 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 8.587021e-01 | 0.066 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 8.587021e-01 | 0.066 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 8.587021e-01 | 0.066 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 8.587021e-01 | 0.066 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 8.587021e-01 | 0.066 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.591400e-01 | 0.066 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 8.591400e-01 | 0.066 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 8.592422e-01 | 0.066 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 8.600995e-01 | 0.065 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 8.600995e-01 | 0.065 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 8.600995e-01 | 0.065 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 8.600995e-01 | 0.065 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 8.659665e-01 | 0.062 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 8.671703e-01 | 0.062 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 8.700330e-01 | 0.060 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 8.700330e-01 | 0.060 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 8.702235e-01 | 0.060 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 8.726710e-01 | 0.059 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 8.726710e-01 | 0.059 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 8.726710e-01 | 0.059 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 8.756032e-01 | 0.058 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 8.756032e-01 | 0.058 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 8.756032e-01 | 0.058 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 8.756032e-01 | 0.058 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 8.784562e-01 | 0.056 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 8.784562e-01 | 0.056 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 8.784562e-01 | 0.056 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 8.784562e-01 | 0.056 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 8.784562e-01 | 0.056 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 8.784562e-01 | 0.056 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 8.784562e-01 | 0.056 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 8.843284e-01 | 0.053 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.850379e-01 | 0.053 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 8.850379e-01 | 0.053 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 8.850379e-01 | 0.053 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 8.850379e-01 | 0.053 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 8.850379e-01 | 0.053 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 8.850379e-01 | 0.053 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 8.850379e-01 | 0.053 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 8.850379e-01 | 0.053 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 8.850379e-01 | 0.053 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 8.857664e-01 | 0.053 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 8.864047e-01 | 0.052 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 8.864047e-01 | 0.052 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 8.864576e-01 | 0.052 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 8.864576e-01 | 0.052 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 8.872279e-01 | 0.052 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 8.887459e-01 | 0.051 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 8.895075e-01 | 0.051 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 8.895075e-01 | 0.051 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 8.895075e-01 | 0.051 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 8.895075e-01 | 0.051 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 8.895075e-01 | 0.051 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 8.901189e-01 | 0.051 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 8.924824e-01 | 0.049 | 0 | 0 |
| Gamma-carboxylation of protein precursors | R-HSA-159740 | 8.954495e-01 | 0.048 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 8.954495e-01 | 0.048 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 8.954495e-01 | 0.048 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 8.954495e-01 | 0.048 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 8.954495e-01 | 0.048 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 8.954495e-01 | 0.048 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 8.954495e-01 | 0.048 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 8.954495e-01 | 0.048 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 8.954495e-01 | 0.048 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 8.954495e-01 | 0.048 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 8.954495e-01 | 0.048 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 8.954495e-01 | 0.048 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 8.954495e-01 | 0.048 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 8.963206e-01 | 0.048 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 8.963206e-01 | 0.048 | 1 | 1 |
| Voltage gated Potassium channels | R-HSA-1296072 | 8.965051e-01 | 0.047 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 8.980995e-01 | 0.047 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 8.982188e-01 | 0.047 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.005361e-01 | 0.045 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 9.019566e-01 | 0.045 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 9.019566e-01 | 0.045 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 9.019566e-01 | 0.045 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 9.019566e-01 | 0.045 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.044937e-01 | 0.044 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.065967e-01 | 0.043 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 9.100677e-01 | 0.041 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 9.100677e-01 | 0.041 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 9.100677e-01 | 0.041 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 9.100677e-01 | 0.041 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 9.100677e-01 | 0.041 | 0 | 0 |
| Gamma-carboxylation, transport, and amino-terminal cleavage of proteins | R-HSA-159854 | 9.100677e-01 | 0.041 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 9.100677e-01 | 0.041 | 0 | 0 |
| Synthesis of GDP-mannose | R-HSA-446205 | 9.100677e-01 | 0.041 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 9.100677e-01 | 0.041 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.111967e-01 | 0.040 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 9.130855e-01 | 0.039 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 9.130855e-01 | 0.039 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.130855e-01 | 0.039 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.130855e-01 | 0.039 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 9.143586e-01 | 0.039 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.143586e-01 | 0.039 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 9.154692e-01 | 0.038 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.159411e-01 | 0.038 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 9.159411e-01 | 0.038 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 9.159411e-01 | 0.038 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 9.208193e-01 | 0.036 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 9.215536e-01 | 0.035 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 9.222107e-01 | 0.035 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 9.222107e-01 | 0.035 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 9.222107e-01 | 0.035 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.222107e-01 | 0.035 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 9.226428e-01 | 0.035 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 9.226428e-01 | 0.035 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 9.226428e-01 | 0.035 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 9.226428e-01 | 0.035 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 9.226428e-01 | 0.035 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 9.226428e-01 | 0.035 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 9.226428e-01 | 0.035 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 9.226428e-01 | 0.035 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 9.226428e-01 | 0.035 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 9.226428e-01 | 0.035 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 9.230199e-01 | 0.035 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 9.230199e-01 | 0.035 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 9.230199e-01 | 0.035 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 9.230199e-01 | 0.035 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 9.247869e-01 | 0.034 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 9.262868e-01 | 0.033 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.266219e-01 | 0.033 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.294098e-01 | 0.032 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.298040e-01 | 0.032 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 9.307650e-01 | 0.031 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 9.307650e-01 | 0.031 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.318762e-01 | 0.031 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.318762e-01 | 0.031 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.318762e-01 | 0.031 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.328131e-01 | 0.030 | 0 | 0 |
| Synthesis of IPs in the nucleus | R-HSA-1855191 | 9.334602e-01 | 0.030 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 9.334602e-01 | 0.030 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 9.334602e-01 | 0.030 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 9.334602e-01 | 0.030 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 9.334602e-01 | 0.030 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 9.334602e-01 | 0.030 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 9.334602e-01 | 0.030 | 0 | 0 |
| Ciprofloxacin ADME | R-HSA-9793528 | 9.334602e-01 | 0.030 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 9.334602e-01 | 0.030 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 9.334602e-01 | 0.030 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 9.334602e-01 | 0.030 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 9.334602e-01 | 0.030 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 9.360014e-01 | 0.029 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 9.386175e-01 | 0.028 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 9.390827e-01 | 0.027 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 9.390827e-01 | 0.027 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.390827e-01 | 0.027 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.390827e-01 | 0.027 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.397617e-01 | 0.027 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 9.397617e-01 | 0.027 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 9.427654e-01 | 0.026 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 9.427654e-01 | 0.026 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 9.427654e-01 | 0.026 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 9.427654e-01 | 0.026 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 9.427654e-01 | 0.026 | 0 | 0 |
| Protein repair | R-HSA-5676934 | 9.427654e-01 | 0.026 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 9.453808e-01 | 0.024 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.454413e-01 | 0.024 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 9.467745e-01 | 0.024 | 0 | 0 |
| Beta-oxidation of pristanoyl-CoA | R-HSA-389887 | 9.467745e-01 | 0.024 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.467745e-01 | 0.024 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.489999e-01 | 0.023 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 9.507698e-01 | 0.022 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 9.507698e-01 | 0.022 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.507698e-01 | 0.022 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 9.507698e-01 | 0.022 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 9.507698e-01 | 0.022 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 9.507698e-01 | 0.022 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 9.507698e-01 | 0.022 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 9.507698e-01 | 0.022 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.522689e-01 | 0.021 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.523841e-01 | 0.021 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.525563e-01 | 0.021 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 9.527459e-01 | 0.021 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 9.530046e-01 | 0.021 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.530046e-01 | 0.021 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 9.543704e-01 | 0.020 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 9.576551e-01 | 0.019 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 9.576551e-01 | 0.019 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 9.576551e-01 | 0.019 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 9.576551e-01 | 0.019 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 9.576551e-01 | 0.019 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 9.585336e-01 | 0.018 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 9.585336e-01 | 0.018 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.585336e-01 | 0.018 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 9.585336e-01 | 0.018 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.598745e-01 | 0.018 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.608235e-01 | 0.017 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.612973e-01 | 0.017 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.612973e-01 | 0.017 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.612973e-01 | 0.017 | 1 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.629887e-01 | 0.016 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.634154e-01 | 0.016 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.634357e-01 | 0.016 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.635779e-01 | 0.016 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.635779e-01 | 0.016 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 9.635779e-01 | 0.016 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.635779e-01 | 0.016 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.635779e-01 | 0.016 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 9.638712e-01 | 0.016 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.649809e-01 | 0.015 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.649853e-01 | 0.015 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.655449e-01 | 0.015 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 9.666183e-01 | 0.015 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.675763e-01 | 0.014 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 9.677781e-01 | 0.014 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 9.686725e-01 | 0.014 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.686725e-01 | 0.014 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 9.686725e-01 | 0.014 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.686725e-01 | 0.014 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.686725e-01 | 0.014 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.687276e-01 | 0.014 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.716214e-01 | 0.013 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.716214e-01 | 0.013 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.719476e-01 | 0.012 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.724780e-01 | 0.012 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.730547e-01 | 0.012 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 9.730547e-01 | 0.012 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.730547e-01 | 0.012 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 9.730547e-01 | 0.012 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.730547e-01 | 0.012 | 0 | 0 |
| Methionine salvage pathway | R-HSA-1237112 | 9.730547e-01 | 0.012 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.730547e-01 | 0.012 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.730547e-01 | 0.012 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.734837e-01 | 0.012 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.734837e-01 | 0.012 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.737647e-01 | 0.012 | 1 | 1 |
| GABA receptor activation | R-HSA-977443 | 9.750570e-01 | 0.011 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.750570e-01 | 0.011 | 1 | 1 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.752219e-01 | 0.011 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.755356e-01 | 0.011 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.760763e-01 | 0.011 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 9.768242e-01 | 0.010 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 9.768242e-01 | 0.010 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.768242e-01 | 0.010 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.768242e-01 | 0.010 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.768242e-01 | 0.010 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 9.778120e-01 | 0.010 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.778120e-01 | 0.010 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.780239e-01 | 0.010 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.790234e-01 | 0.009 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 9.800665e-01 | 0.009 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 9.800665e-01 | 0.009 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.800665e-01 | 0.009 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 9.800665e-01 | 0.009 | 0 | 0 |
| Abacavir metabolism | R-HSA-2161541 | 9.800665e-01 | 0.009 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.800665e-01 | 0.009 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.800665e-01 | 0.009 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.800665e-01 | 0.009 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.800850e-01 | 0.009 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.802358e-01 | 0.009 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.803492e-01 | 0.009 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.803689e-01 | 0.009 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.806762e-01 | 0.008 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.814532e-01 | 0.008 | 0 | 0 |
| CS-GAG biosynthesis | R-HSA-2022870 | 9.828553e-01 | 0.008 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.828553e-01 | 0.008 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.828553e-01 | 0.008 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.828553e-01 | 0.008 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.828553e-01 | 0.008 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.830167e-01 | 0.007 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.830167e-01 | 0.007 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 9.841022e-01 | 0.007 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.850807e-01 | 0.007 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.850807e-01 | 0.007 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.850807e-01 | 0.007 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.850807e-01 | 0.007 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.852542e-01 | 0.006 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.852554e-01 | 0.006 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.865994e-01 | 0.006 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.868998e-01 | 0.006 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.873175e-01 | 0.006 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 9.873175e-01 | 0.006 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.873175e-01 | 0.006 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 9.873175e-01 | 0.006 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.873175e-01 | 0.006 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.876301e-01 | 0.005 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.879893e-01 | 0.005 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.885020e-01 | 0.005 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.885020e-01 | 0.005 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.885020e-01 | 0.005 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.890039e-01 | 0.005 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.890922e-01 | 0.005 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.890922e-01 | 0.005 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.893545e-01 | 0.005 | 1 | 0 |
| rRNA processing | R-HSA-72312 | 9.898015e-01 | 0.004 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.899125e-01 | 0.004 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.899125e-01 | 0.004 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.900277e-01 | 0.004 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 9.903678e-01 | 0.004 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.906186e-01 | 0.004 | 0 | 0 |
| Alpha-oxidation of phytanate | R-HSA-389599 | 9.906186e-01 | 0.004 | 0 | 0 |
| Retinoid cycle disease events | R-HSA-2453864 | 9.906186e-01 | 0.004 | 0 | 0 |
| Diseases of the neuronal system | R-HSA-9675143 | 9.906186e-01 | 0.004 | 0 | 0 |
| Diseases associated with visual transduction | R-HSA-2474795 | 9.906186e-01 | 0.004 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.906186e-01 | 0.004 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.909895e-01 | 0.004 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.913450e-01 | 0.004 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.918872e-01 | 0.004 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.918872e-01 | 0.004 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.919316e-01 | 0.004 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.919316e-01 | 0.004 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.922917e-01 | 0.003 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.923240e-01 | 0.003 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.925268e-01 | 0.003 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.930608e-01 | 0.003 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.930608e-01 | 0.003 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.930608e-01 | 0.003 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.930608e-01 | 0.003 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.931954e-01 | 0.003 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.932039e-01 | 0.003 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.940320e-01 | 0.003 | 0 | 0 |
| Iron assimilation using enterobactin | R-HSA-9638334 | 9.940320e-01 | 0.003 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.940466e-01 | 0.003 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 9.941730e-01 | 0.003 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.941914e-01 | 0.003 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 9.942217e-01 | 0.003 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.943296e-01 | 0.002 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.946601e-01 | 0.002 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.947866e-01 | 0.002 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.947866e-01 | 0.002 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.947866e-01 | 0.002 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.947866e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.947866e-01 | 0.002 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.948674e-01 | 0.002 | 0 | 0 |
| Translation | R-HSA-72766 | 9.954613e-01 | 0.002 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 9.955275e-01 | 0.002 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.957233e-01 | 0.002 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 9.959481e-01 | 0.002 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.960060e-01 | 0.002 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.960806e-01 | 0.002 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.960958e-01 | 0.002 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 9.962038e-01 | 0.002 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.965058e-01 | 0.002 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.965058e-01 | 0.002 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 9.965199e-01 | 0.002 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.967283e-01 | 0.001 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.967353e-01 | 0.001 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.969440e-01 | 0.001 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.969440e-01 | 0.001 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.971923e-01 | 0.001 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.971923e-01 | 0.001 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.974451e-01 | 0.001 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.974451e-01 | 0.001 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.974451e-01 | 0.001 | 0 | 0 |
| CS/DS degradation | R-HSA-2024101 | 9.975854e-01 | 0.001 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.977436e-01 | 0.001 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.977436e-01 | 0.001 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.978582e-01 | 0.001 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.979235e-01 | 0.001 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.979235e-01 | 0.001 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 9.981895e-01 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 9.982143e-01 | 0.001 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.982169e-01 | 0.001 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.984644e-01 | 0.001 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.984644e-01 | 0.001 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.986319e-01 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.986402e-01 | 0.001 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.986794e-01 | 0.001 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.986794e-01 | 0.001 | 0 | 0 |
| Lysine catabolism | R-HSA-71064 | 9.986794e-01 | 0.001 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.986794e-01 | 0.001 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.987194e-01 | 0.001 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.988422e-01 | 0.001 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 9.988644e-01 | 0.000 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.988644e-01 | 0.000 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.988644e-01 | 0.000 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.989369e-01 | 0.000 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.990234e-01 | 0.000 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.990234e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.990633e-01 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.990735e-01 | 0.000 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.990970e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.990970e-01 | 0.000 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.991602e-01 | 0.000 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.991602e-01 | 0.000 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.992113e-01 | 0.000 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.993592e-01 | 0.000 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.993603e-01 | 0.000 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.993790e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.993933e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.994371e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.994371e-01 | 0.000 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.994660e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.996357e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.996406e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.996539e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.996539e-01 | 0.000 | 0 | 0 |
| The canonical retinoid cycle in rods (twilight vision) | R-HSA-2453902 | 9.996605e-01 | 0.000 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.996605e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.996888e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.996888e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.996987e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.997219e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.997374e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.997469e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.997490e-01 | 0.000 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.998144e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.998491e-01 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.998521e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.998922e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.998955e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.999135e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.999248e-01 | 0.000 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 9.999250e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.999355e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999393e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.999451e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.999506e-01 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.999543e-01 | 0.000 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.999587e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.999590e-01 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.999621e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.999648e-01 | 0.000 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.999786e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.999787e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.999797e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999857e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999876e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.999878e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999890e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.999895e-01 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.999895e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999909e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999916e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.999933e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999944e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.999949e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999951e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999957e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.999958e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999971e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.999977e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999977e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999978e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999980e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999985e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999990e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999991e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999995e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.999996e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.999996e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999997e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999998e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999999e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.999999e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999999e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999999e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999999e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 1 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 1 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 1 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |